



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁷ : C07D 417/14, 401/14, A61K 31/549, 31/5415, 31/475, 31/454, C07D 285/16, 285/10, 215/22, 215/36, 209/34</p>	A2	<p>(11) International Publication Number: WO 00/31074</p> <p>(43) International Publication Date: 2 June 2000 (02.06.00)</p>		
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top; padding: 5px;"> <p>(21) International Application Number: PCT/GB99/03836</p> <p>(22) International Filing Date: 18 November 1999 (18.11.99)</p> <p>(30) Priority Data: 9825413.9 19 November 1998 (19.11.98) GB</p> <p>(71) Applicant: ELI LILLY AND COMPANY LIMITED [GB/GB]; Kingsclere Road, Basingstoke, Hampshire RG21 6XA (GB).</p> <p>(72) Inventors: FAIRHURST, John; 17 Hinton Fields, Kings Worthy, Winchester, Hampshire SO23 7QB (GB). GALLAGHER, Peter, Thaddeus; 27 Ryves Avenue, Yateley, Hampshire GU46 6FB (GB). MILES, Martin, Victor; 21 Wensleydale Gardens, Hampton, Middlesex TW12 2LU (GB).</p> <p>(74) Agent: HUDSON, Christopher, Mark; Eli Lilly and Company Limited, Lilly Research Centre, Erl Wood Manor, Windlesham, Surrey GU20 6PH (GB).</p> </td> <td style="width: 50%; vertical-align: top; padding: 5px;"> <p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published Without international search report and to be republished upon receipt of that report.</p> </td> </tr> </table>			<p>(21) International Application Number: PCT/GB99/03836</p> <p>(22) International Filing Date: 18 November 1999 (18.11.99)</p> <p>(30) Priority Data: 9825413.9 19 November 1998 (19.11.98) GB</p> <p>(71) Applicant: ELI LILLY AND COMPANY LIMITED [GB/GB]; Kingsclere Road, Basingstoke, Hampshire RG21 6XA (GB).</p> <p>(72) Inventors: FAIRHURST, John; 17 Hinton Fields, Kings Worthy, Winchester, Hampshire SO23 7QB (GB). GALLAGHER, Peter, Thaddeus; 27 Ryves Avenue, Yateley, Hampshire GU46 6FB (GB). MILES, Martin, Victor; 21 Wensleydale Gardens, Hampton, Middlesex TW12 2LU (GB).</p> <p>(74) Agent: HUDSON, Christopher, Mark; Eli Lilly and Company Limited, Lilly Research Centre, Erl Wood Manor, Windlesham, Surrey GU20 6PH (GB).</p>	<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published Without international search report and to be republished upon receipt of that report.</p>
<p>(21) International Application Number: PCT/GB99/03836</p> <p>(22) International Filing Date: 18 November 1999 (18.11.99)</p> <p>(30) Priority Data: 9825413.9 19 November 1998 (19.11.98) GB</p> <p>(71) Applicant: ELI LILLY AND COMPANY LIMITED [GB/GB]; Kingsclere Road, Basingstoke, Hampshire RG21 6XA (GB).</p> <p>(72) Inventors: FAIRHURST, John; 17 Hinton Fields, Kings Worthy, Winchester, Hampshire SO23 7QB (GB). GALLAGHER, Peter, Thaddeus; 27 Ryves Avenue, Yateley, Hampshire GU46 6FB (GB). MILES, Martin, Victor; 21 Wensleydale Gardens, Hampton, Middlesex TW12 2LU (GB).</p> <p>(74) Agent: HUDSON, Christopher, Mark; Eli Lilly and Company Limited, Lilly Research Centre, Erl Wood Manor, Windlesham, Surrey GU20 6PH (GB).</p>	<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published Without international search report and to be republished upon receipt of that report.</p>			
<p>(54) Title: INDOLE DERIVATIVES AND THEIR USE AS SEROTONIN RECEPTOR LIGANDS</p> <div style="text-align: center; margin: 20px 0;"> <p style="margin-top: 10px;">(I)</p> </div> <div style="display: flex; justify-content: space-around; margin: 20px 0;"> <div style="text-align: center;"> <p>(1)</p> </div> <div style="text-align: center;"> <p>(2)</p> </div> </div> <div style="display: flex; justify-content: space-around; margin: 20px 0;"> <div style="text-align: center;"> <p>(3)</p> </div> <div style="text-align: center;"> <p>(4)</p> </div> </div>				
<p>(57) Abstract</p> <p>A pharmaceutical compound of formula (I) in which R¹ and R² are each hydrogen, halo, cyano or methyl, the dotted line represents an optional double bond, X is (1) or (2), Y is (3) or (4) where R⁴ and R⁵ are each hydrogen, C₁₋₆ alkyl, cyclopropyl or cyclopropyl-C₁₋₆ alkyl, n is 0 or 1, and R³ is -SR⁶, -SOR⁶, -SO₂R⁶, -COR⁶, -CH₂OH or -CONHR⁷, where R⁶ is C₁₋₆ alkyl and R⁷ is hydrogen or C₁₋₆ alkyl; provided that when one of R¹ and R² is hydrogen and the other is fluoro, X is (1), Y is (4), R⁴ and R⁵ are each hydrogen or C₁₋₆ alkyl, and n is 0, then R³ is not -COR⁶ or -CONHR⁷; and salts thereof.</p>				

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INDOLE DERIVATIVES AND THEIR USE AS SEROTONIN RECEPTOR LIGANDS

This invention relates to pharmaceutical compounds and their use in the treatment of disorders of the central nervous system.

It is well known that compounds active at serotonin receptors have potential in the treatment of disorders of the central nervous system and, for example, certain halo-substituted indole compounds having serotonin antagonist properties are disclosed in WO 98/31686.



The compounds of the invention have the following formula:



(I)

in which R¹ and R² are each hydrogen, halo, cyano or methyl,

the dotted line represents an optional double bond,



5


where R^4 and R^5 are each hydrogen, C_{1-6} alkyl, cyclopropyl or cyclopropyl- C_{1-6} alkyl,

10 n is 0 or 1, and

R^3 is $-SR^6$, $-SOR^6$, $-SO_2R^6$, $-COR^6$, $-CH_2OH$ or $-CONHR^7$,

where R^6 is C_{1-6} alkyl and R^7 is hydrogen or C_{1-6} alkyl;

15 provided that when one of R^1 and R^2 is hydrogen and the other is fluoro,



R^4 and R^5 are each hydrogen or C_{1-6} alkyl,

and n is 0,

5 then R^3 is not $-COR^6$ or $-CONHR^7$;

and salts thereof.


The compounds of the invention and their
10 pharmaceutically acceptable salts are indicated for use
in the treatment of disorders of the central nervous
system.

In the above formula (I), a halo atom is preferably
15 chloro, bromo or fluoro, and is especially fluoro. A
 C_{1-6} alkyl group can be methyl, ethyl, propyl, butyl or
pentyl, and can be branched or unbranched including
isopropyl and tert. butyl.


20 Preferred compounds are those which have one or more of
the following features:

(i) R^1 and R^2 are each hydrogen or halo;

- (ii) R^1 and R^2 are each hydrogen or fluoro;
- (iii) R^1 is fluoro and R^2 is hydrogen;
- 5 (iv) R^1 is fluoro in the 6-position, and R^2 is hydrogen;
- (v) the dotted line represents a double bond;
- 10 (vi)




(vii)



15

(viii) R^4 and R^5 are each hydrogen or C_{1-6} alkyl;

(ix)



20

where R^4 is C_{1-6} alkyl, especially isopropyl;

(x) n is 1;

(xi) n is 1 and R³ is at the 6-position;


5

(xii) R³ is -SOR⁶, -SO₂R⁶ or -COR⁶;

(xiii) R⁶ is methyl or ethyl, and especially methyl;

10 (xiv) R³ is -SOCH₃ or -SO₂CH₃, at the 6-position.

A preferred group of compounds is of the following formula:



15

(II)


in which R¹ and R² are each hydrogen or fluoro,

R^3 is at the 6- or 7- position and is $-SOR^6$, $-SO_2R^6$ or $-COR^6$, where R^4 and R^6 are each C_{1-6} alkyl, especially methyl or ethyl.

5

Especially preferred are compounds of formula (II) in which R^1 is fluoro, R^2 is hydrogen, R^3 is at the 6-position, R^4 is C_{1-6} alkyl, preferably isopropyl, R^6 is preferably methyl, and preferably the dotted bond
10 represents a double bond.

Especially preferred compounds are of the formula:



(III)

15


where R^3 is $-SOCH_3$ or $-SO_2CH_3$, or a pharmaceutically acceptable salt thereof.

As indicated above, it is, of course, possible to prepare salts of the compound of the invention and such salts are included in the invention. Acid addition salts are preferably the pharmaceutically acceptable, non-toxic addition salts with suitable acids, such as those with inorganic acids, for example hydrochloric, hydrobromic, nitric, sulphuric or phosphoric acids, or with organic acids, such as organic carboxylic acids, for example, pyruvic, lactobionic, glycollic, maleic, hydroxymaleic, fumaric, malic, tartaric, citric, salicylic, o-acetoxybenzoic, or organic sulphonic, 2-hydroxyethane sulphonic, toluene-p-sulphonic, naphthalene-2-sulphonic, bisethanesulphonic acid or methanesulphonic acid. A preferred salt is the tartrate.


In addition to the pharmaceutically acceptable salts, other salts are included in the invention. They may serve as intermediates in the purification of compounds or in the preparation of other, for example pharmaceutically acceptable, acid addition salts, or are useful for identification, characterisation or purification.

Some of the compounds of the invention contain one or more asymmetric carbon atoms which gives rise to isomers. Moreover, compounds which are substituted by a sulphinyl group (R^3 is $-SOR^6$) also exist in isomeric forms. These compounds are normally prepared as racemic mixtures and can conveniently be used as such, but individual isomers can be isolated by conventional techniques, if so desired. Such racemic mixtures and individual optical isomers form part of the present invention. It is preferred to use an enantiomerically pure form.

The invention also includes a process for producing a compound of formula (I) above, which comprises reacting a compound of the formula:



with a compound of the formula



(V)

where n , R^1 , R^2 , R^3 , X and Y have the values given above, and (i) Z is $-CH_2W$, where W is a leaving group


5 such as, for example, a halo atom or a mesylate or tosylate, or (ii) Z is $-CHO$.

The reaction is preferably carried out in a polar solvent such as, for example, acetonitrile or water, at
10 a temperature of from $50^\circ C$. to $150^\circ C$., and in the presence of sodium iodide and a base such as, for example, sodium carbonate. When an aldehyde intermediate is employed, the reaction is one of reductive amination using, for example, sodium
15 cyanoborohydride, borane in pyridine or triacetoxy borohydride in the presence of the compound of formula (IV).

The intermediate compounds of formula (IV) are known in
20 the art, whereas compounds of formula (V), and their

salts, in which n is 1, are novel. Compounds of formula (V) can be prepared by reacting an ethane derivative of the formula $V-CH_2CH_2-W$ (VI), where V is halo, preferably bromo, with a compound of

5 formula:



(VII)


Preferred ethane derivatives of formula (VI) are dihalo-

10 ethanes, for instance bromo chloroethane, and the reaction is preferably carried out in an organic solvent such as, for example, dimethyl formamide, with a strong base such as sodium hydride, at a temperature of from 0°C. to 100°C. , for instance room temperature.

15


Aldehyde intermediates of formula (V) can be prepared from the appropriate alkene by oxidation employing, for example, ozone or osmium tetroxide.

Alternatively, compounds of formula (V) can be prepared by a synthetic route, such as the following:




5

or by the following route:



The intermediate compounds of formula (VII) are known in the literature, and they can readily be prepared by a variety of routes as, for example, in the case of compounds of formula (VII) having the following structure:




(VIII)

the principal route of synthesis is by means of a reaction between the appropriate sulfamoyl compound prepared from an aniline and sulfamoyl chloride and trioxan, in the presence of an acid, for example, an alkyl sulfonic acid:




Alternatively, compounds of formula (VIII) can be synthesised by reaction of sulfamide with an amino benzylamine in pyridine or diglyme. The amino benzylamine can be prepared in three steps from the appropriate nitrobenzoic acid via amide formation and a two step reduction as, for example:

15




A further alternative route to compounds of formula (VIII) involves the use of an appropriate N-sulfamoyloxazolidinone of formula:



5

which can be readily prepared by reacting chlorosulfonylisocyanate and amine with chloro- or bromo-ethanol. The N-sulfamoyloxazolidinone is then reacted with an aniline of formula




and the resulting sulfonyl urea reacted with trioxan, as described above, to give the compound of formula (VIII).

An alternative route to the compounds of the invention in which in formula (I) X is:

20



consists of an analogous, reverse, condensation of the two principal components of the molecule as, for
 5 example, by reacting a compound of the formula:



(IX)

with a compound of formula (VIII) above, employing the
 10 Mitsunobu reaction. The reaction is carried out in an organic solvent such as tetrahydrofuran or dimethyl formamide, at a temperature of, for example, 0°C. to 5°C. employing a dialkylazodicarboxylate and triphenylphosphine or tributylphosphine. Intermediate
 15 compounds of formula (IX) are novel and are included as part of the present invention.

It will be appreciated that in preparing compounds of formula (I) in which R³ is -SOR⁶ or -SO₂R⁶, the

appropriate intermediates as, for example, those of formula (VIII), can be prepared by oxidation of the -SR⁶ substituted compound, by the use of metachloro perbenzoic acid or Oxone® or sodium perborate or osmium tetroxide/sodium periodate.

As mentioned above, the compounds of the invention and their pharmaceutically acceptable salts have useful central nervous system activity. They have been shown to increase release of tritiated-5HT from guinea pig cortical slices in a test with the following procedure.

Cortical slices from the brains of male guinea pigs were incubated with 50 nM [³H]-5-HT for 30 minutes at 37° C. The slices were washed in basal buffer containing 1 μM paroxetine and then transferred to baskets. The baskets were used to transfer the tissue between the washing and release buffers, all of which contained 1 μM paroxetine.

20

In order to obtain a stable baseline release, the slices were incubated for 11 minutes in buffer and then transferred for 4 minutes to a second tube containing buffer. Following incubation they were again

transferred, for a further 4 minutes, to a buffer in which NaCl had been substituted, on an equimolar basis, to give a KCl concentration of 30 mM (release sample). The tritium in the tissue samples and in the buffers
5 from the three incubation periods was estimated by liquid scintillation spectroscopy. Test compound was present throughout the three incubation periods. The compounds of the invention enhanced release of 5-HT by greater than 35% at 1 μ M concentration.

10

Compounds of the invention have also been demonstrated to be active at the serotonin, 5-HT_{2A}, receptor. Their binding activity has been demonstrated in a test described by Nelson, D. L. et al, J. Pharmacol. Exp.
15 Ther., 265, 1272-1279, in which the affinity of the compound for the human 2A receptor is measured by its ability to displace the ligand [³H]-ketanserin. Compounds of the invention are also active serotonin reuptake inhibitors as measured by their displacement of
20 [³H]-paroxetine at the reuptake site, Neuropharmacology Vol. 32 No. 8, 1993, pages 737-743.

Because of their ability to enhance 5-HT release as well as selective affinity for 5-HT receptors, the compounds

of the present invention are indicated for use in treating a variety of conditions such as depression, obesity, bulimia, alcoholism, pain, hypertension, ageing, memory loss, sexual dysfunction, anxiety, 5 schizophrenia, gastrointestinal disorders, headache, cardiovascular disorders, smoking cessation, drug addiction, emesis, epilepsy, Alzheimer's and sleep disorders.

10 The compounds of the invention are effective over a wide dosage range, the actual dose administered being dependent on such factors as the particular compound being used, the condition being treated and the type and size of mammal being treated. However, the dosage 15 required will normally fall within the range of 0.01 to 20 mg/kg per day, for example in the treatment of adult humans, dosages of from 0.1 to 100 mg per day may be used, preferably from 2 to 20 mg per day as, for example, for the preferred compounds of formula (II) and 20 (III).

The compounds of the invention will normally be administered orally or by injection and, for this purpose, the compounds will usually be utilised in the

form of a pharmaceutical composition. Such compositions are prepared in a manner well known in the pharmaceutical art and comprise at least one active compound.

5

Accordingly the invention includes a pharmaceutical composition comprising as active ingredient a compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, associated with a pharmaceutically acceptable excipient. In making the compositions of the invention, the active ingredient will usually be mixed with a carrier, or diluted by a carrier, or enclosed within a carrier which may be in the form of a capsule, sachet, paper or other container. The excipient may be a solid, semi-solid or liquid material which acts as a vehicle, excipient or medium for the active ingredient. Some examples of suitable excipients are lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin syrup, methyl cellulose, methyl- and propyl-hydroxybenzoate, talc, magnesium stearate or oil. The compositions of the invention may, if desired, be formulated so as to provide quick, sustained or delayed

10

15

20

release of the active ingredient after administration to the patient.

Depending on the route of administration, the foregoing
5 compositions may be formulated as tablets, capsules or
suspensions for oral use and injection solutions or
suspensions for parenteral use or as suppositories.
Preferably the compositions are formulated in a dosage
unit form, each dosage containing from 0.1 to 100 mg,
10 more usually 2 to 20 mg, of the active ingredient.

The following Preparations and Examples illustrate
routes to the synthesis of the compounds of the
invention.

PREPARATIONS**1-Dimethylamino-2-(4-fluoro-2-nitro)phenylethene**

A mixture of 4-fluoro-2-nitrotoluene (50 g,
5 0.32 mol), dimethylformamide dimethylacetal
(76.77 g) and dimethylformamide (910 ml) were
heated under reflux under nitrogen with stirring
for 7 hr, cooled, allowed to stand for 16 hr,
poured into ice-water (2 l), stirred for 15 mins
10 and the resultant precipitate isolated by
filtration, washed with water (500 ml), dried to

ethyl acetate-hexane (7:3) and filtered through a pad of flash silica. The required fractions were collected and evaporated under reduced pressure to give a pale brown solid. (Org. Synth. (1985), 63, 214-25)

7-Fluoro-1H-indole

2-Fluoro-1-nitrobenzene (20.0 g, 0.142 mol) was dissolved in dry tetrahydrofuran (400 ml) and cooled to -50°C. Vinylmagnesium chloride (288 ml, 15% wt/vol) was added at -45°C and stirred at this temperature for 1 hr. The reaction mixture was then poured onto saturated ammonium chloride (600 ml), separated and the aqueous layer extracted with diethyl ether (2 x 200 ml) then dried (MgSO₄), filtered and concentrated *in vacuo* to yield a dark oil which was purified by column chromatography on silica using toluene as mobile phase. Fractions concentrated to yield a crystalline solid. (Tetrahedron Lett. (1989), 30(16), 2129-32)

7-Fluoro-1H-indole (Alternative preparation)

To a stirred solution of boron trichloride in dichloromethane (1.0 M, 3.650 l, 3.65 mol) at -10°C under nitrogen was added 2-fluoroaniline (387 g,

3.48 mol) and the temperature rose to 18°C. The mixture was stirred for 45 mins before chloroacetonitrile (300 g, 3.97 mol) followed by aluminium chloride (500 g, 3.75 mol) were added.

5 1,2-Dichloroethane (5.7 l) was then added, the mixture heated and the dichloromethane distilled from the reaction vessel. The dichloroethane solution was then heated at 78-80°C. for 18 hr. The reaction mixture was then cooled to 2°C and

10 hydrochloric acid (2.5M, 450 ml) was added slowly with a resultant exotherm. More hydrochloric acid (2.5M, 5.55 l) was added and then the mixture was warmed to reflux for 10 mins then cooled. The dichloroethane layer was separated and the aqueous

15 layer extracted with dichloromethane (1 l) combined with the dichloroethane, washed with brine (2 l), dried (MgSO₄), filtered and the solvent evaporated *in vacuo* to give a solid 321.7 g. This solid was dissolved in a mixture of dioxan (10 l) and water

20 (1 l) and treated under nitrogen with sodium borohydride (73.0 g, 1.93 mol) then heated under reflux for 1 hour. More sodium borohydride (12 g) was added and the mixture heated for a further 3 hr, cooled to 45°C and the solvent removed *in*

25 *vacuo*. The residue was partitioned between dichloromethane (2 l) and water (2 l). The organic layer was separated, dried (MgSO₄), filtered and

evaporated in vacuo to give an oil which was further purified by filtering through silica.

Similarly prepared were:

5 **6,7-Difluoro-1H-indole**

δ (^1H NMR, CDCl_3 , ppm) : 6.50 (1H, m), 6.90 (1H, m), 7.30 (2H, m), 8.4 (1H, br).

6-Fluoro-7-methyl-1H-indole (J.Med.Chem., 1976
19(3) 391-5)

10

δ (^1H NMR, CDCl_3 , ppm) : 2.4 (3H, s), 6.50 (1H,), 6.90 (1H, t), 7.20 (1H, m), 7.4 (1H, m), 8.0 (1H, s).

15

6-Fluoro-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (EP 722941)

20

Powdered potassium hydroxide (144.4 g) was added carefully to a mechanically stirred mixture of 6-fluoroindole (49.23 g, 0.364 mol) and 4-piperidone monohydrate (111.93 g, 0.728 mol) in methanol (1500 ml). The mixture was then heated under reflux under nitrogen for 18 hr and then more potassium hydroxide (40 g) was added and the reaction mixture heated under reflux for a further 4 hr. The reaction mixture was allowed to cool to room temperature and poured onto ice-water (3 l)

25

and stirred for 1 hr and the precipitated solid isolated by filtration and dried at 50°C *in vacuo* to give a solid. (WO 9747302).

Similarly prepared were

5 5-Fluoro-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (J.Med.Chem., 1993 36(9) 1194).

6,7-Difluoro-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole

10 δ (¹H NMR, MeOD, ppm) : 2.5 (2H, m), 3.0 (2H, t), 3.50 (2H), 6.20 (1H), 6.90 (1H, m), 7.3 (1H, s), 7.50 (1H, m).

6-Fluoro-7-methyl-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole

15

δ (¹H NMR, DMSO, ppm) : 2.4 (4H, br), 3.0 (2H, m), 3.50 (2H), 6.20 (1H), 6.90 (1H, t), 7.4 (1H, s), 7.60 (1H, m), 11.2 (1H, br).

3-(1,2,3,6-Tetrahydro-4-pyridinyl)-1H-indole

20 (J.Med.Chem., 1992 35(26) 4813-22)

6-Chloro-3-(1,2,3,6-Tetrahydro-4-pyridinyl)-1H-indole (EP 722941)

7-Fluoro-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (WO 9747302)

6-Fluoro-3-(4-piperidinyl)-1H-indole

5 A mixture of platinum oxide (1.0 g) in ethanol (37.5 ml) and glacial acetic acid (12.5 ml) were mixed under nitrogen with 6-fluoro-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (20 g, 0.0926 mol) in ethanol (187.5 ml) and glacial acetic acid (62.5 ml). The reaction mixture was then
10 hydrogenated at 60 psi until the reaction was complete by tlc. The catalyst was removed by filtration and the solvent evaporated in vacuo to give a yellow solid which was dried at 60°C. in vacuo (EP 722941).

15

Similarly prepared were

5-Fluoro-3-(4-piperidinyl)-1H-indole (EP 705600)

6,7-Difluoro-3-(4-piperidinyl)-1H-indole

20 δ (^1H NMR, MeOD, ppm) : 1.6-1.8 (2H, m), 1.95-2.05 (2H, m), 2.70-3.00 (3H, m), 3.00-3.20 (2H, d), 6.80 (1H, m), 7.0 (1H, s), 7.30 (1H, m).

6-Chloro-3-(4-piperidinyl)-1H-indole (WO 9747302).

3-(4-Piperidinyl)-1H-indole (Helv Chim Acta 1968
25 51(2) 260-264).

2-(4-(6-Fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl)ethanol.

To a stirred solution of 6-fluoro-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (1.0 g, 0.00462 mol) and triethylamine (0.77 ml, 0.00555 mol) in DMF (60ml), was added dropwise under nitrogen 2-bromoethanol (0.42 ml, 0.00555 mol) then allowed to stir at room temperature overnight. Workup involved addition of ethyl acetate (80 ml) and water (50 ml), the organic layer was washed with water (4 x 50 ml). The organic layer was dried (MgSO₄) and concentrated *in vacuo* to afford 2-(4-(6-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl)ethanol as a yellow solid 1.02 g.

δ (¹H NMR, DMSO, ppm) : 11.3 (1H, s), 8.0 (1H, q), 7.5 (1H, s), 7.3 (1H, q), 7.0 (1H, m), 6.3 (1H, m), 4.6 (1 H, s), 3.7 (2H, t), 3.5 (2H, m), 3.4 (2H, m), 2.8 (2H, m), 2.6 (2H, t).

20

(1-Methylethyl)sulfamic acid

A 250 ml 3-necked round bottom flask equipped with a magnetic stirrer bar, pressure equalising dropping funnel, thermometer and nitrogen gas bleed

was charged with nitromethane (75 ml) and fuming sulfuric acid (30 g, i.e. oleum 12-17%). The mixture was cooled to 0°C. using an external cardice (solid CO₂)/acetone bath. Then isopropyl isocyanate (25 g, 0.294 mol) was added dropwise to the mixture, stirred under nitrogen, keeping the temperature below 30°C. during the addition. The stirred suspension was then heated under reflux for 30 mins, then allowed to cool to room temperature and stirred overnight. Diethyl ether (100 ml) was added to the mixture, which was then filtered. The filter pad was washed with more ether (3 x 100 ml) and then dried in an air stream at room temperature to give a pale yellow crystalline solid, (1-methyl ethyl)sulfamic acid. (JOC 1976 41 (25) 4028-9)

Similarly prepared was ethylsulfamic acid (JOC 1976 41 (25) 4028-9)

20 (1-Methylethyl)sulfamoyl chloride

A 500 ml 3-necked round bottom flask equipped with a water condenser, thermometer and magnetic stirrer bar was charged with (1-methyl ethyl)sulfamic acid (34.8 g, 0.25 mol), phosphorus pentachloride

(52.06 g, 0.25 mol) and toluene (400 ml). The mixture was warmed under reflux for 1 hr, then cooled back down to room temperature. The solvent was removed *in vacuo* to give a pale brown oil which was then purified by distillation under reduced pressure (approximately 15 mm Hg and 110°C.) to give a clear, colourless liquid, (1-methyl ethyl)sulfamoyl chloride (JOC 1976 41 (25) 4028-9)

Similarly prepared was ethylsulfamoyl chloride (JOC 1976 41 (25) 4028-9).

1-(Ethylthio)-4-nitrobenzene (Precursors for the synthesis of N-(4-ethylsulfonylphenyl)-N'-(1-methylethyl)sulfamide.

Ethanethiol (6.11 ml, 0.082 mol) was added slowly to a suspension of sodium hydride (3.3 g, 60% dispersion) in dry dimethylformamide (225 ml) at room temperature under a nitrogen atmosphere. The reaction mixture was stirred for 15 min before the addition of 1-chloro-4-nitrobenzene (10 g, 0.063 mol) dissolved in dry dimethylformamide (25 ml). After addition, the resultant mixture was allowed to warm to 60°C. and was stirred for 24 hr. The mixture was then concentrated *in vacuo* to yield a

yellow oil. Ice and water were added and a yellow solid was precipitated and filtered off. The solid was then dissolved in methanol (100 ml) and insoluble by-products were isolated by filtration.

5 The filtrate was then concentrated in vacuo. The residue was dissolved in ethyl acetate (50 ml) and washed with water (2 x 50 ml). The organic layer was then dried (MgSO_4) and concentrated in vacuo to afford 1-(ethylthio)-4-nitrobenzene as a yellow

10 solid. δ (^1H NMR, DMSO, ppm) : 1.15 (3H, t), 3.05 (2H, q), 7.45 (2H, d), 8.10 (2H, d).

1-(Ethylsulfonyl)-4-nitrobenzene

1-(Ethylthio)-4-nitrobenzene (9 g, 0.049 mol) was

15 dissolved in chloroform (500 ml). 3-chloroperoxybenzoic acid (21.14 g, 0.123 mol) was then added to the solution. After stirring at room temperature for 2 hr, the reaction mixture was filtered through celite. The filtrate was then

20 dried (MgSO_4) and concentrated in vacuo to yield 1-(ethylsulfonyl)-4-nitrobenzene. δ (^1H NMR, DMSO, ppm) : 1.15 (3H, t), 3.40 (2H, q), 8.10 (2H, d), 8.40 (2H, d).

4-(Ethylsulfonyl)benzene amine

Tin (II) chloride dihydrate (51.89 g, 0.230 mol) was added to 1-(ethylsulfonyl)-4-nitrobenzene (10 g, 0.046 mol) in ethanol (250 ml) then heated under reflux for 16 h. The mixture was cooled to room temperature and treated with aqueous sodium hydroxide (2N, 100 ml). The product was then extracted into ethyl acetate (3 x 150 ml). The organic extracts were combined, dried (MgSO₄) and concentrated *in vacuo*. The residue was then purified by chromatography column over silica (50% ethyl acetate/50% petroleum ether) to afford 4-(ethylsulfonyl)-benzene amine. δ (¹H NMR, DMSO, ppm) : 1.00 (3H, t), 2.95 (2H, q), 5.95 (2H, s), 6.55 (2H, d), 7.35 (2H, d).

5-Methylthio-2-nitrobenzoic acid.

5-Chloro-2-nitrobenzoic acid (25.2 g, 0.125 mol) was stirred in water. To this was added sufficient sodium hydroxide solution (2M, 42 ml, 0.084 mol) to dissolve the acid completely. A solution of sodium sulfide nonahydrate (33.0 g, 0.1375 mol) in water (75 ml) was added and the solution was stirred at 60 °C for 2.5 hr. This resultant red solution was

added to a solution of sodium hydroxide (50% 10 ml,
0.125 mol) in water (15 ml), dimethyl sulfate (24
ml, 0.25 mol) was added and the solution heated
under reflux for 1 hour. The solution was cooled
and acidified with hydrochloric acid (5M, 32 ml,
0.16 mol). The precipitated yellow solid was
filtered off, washed with water, dried at 60°C.
under vacuum, mp 173°C. (lit. J. Heterocyclic
Chemistry 1981 18 117). Mp 175-178°C.)

N-Cyclopropylmethyl-5-methylthio-2-nitrobenzamide.

To a suspension of 5-methylthio-2-nitrobenzoic acid
(13.84 g, 0.065 mol) in hexane (130 ml) was added
thionyl chloride (35 ml, 0.1298 mol) and heated
under reflux for 1 hour by which time the acid had
dissolved. The resultant reaction mixture was
decanted from a tar-like material which had
precipitated from the reaction mixture and the
hexane solution was then evaporated *in vacuo* to
give a yellow crystalline acid chloride (14.59 g,
97 %, Mp 72°C.) which was used without further
purification. The acid chloride (14.59 g, 0.063
mol) was dissolved in THF (60 ml) and added
dropwise to a solution of cyclopropylmethylamine

(5.8 g, 0.066 mol) and triethylamine (9.3 ml, 0.066 mol) in THF (60 ml) with mechanical stirring and ice-bath cooling to maintain the reaction at below 10°C. After all the acid chloride had been added
5 the reaction mixture was allowed to warm to room temperature and stirred for 1 hr. The reaction mixture was then partitioned between chloroform and water, the organic phase was washed with water, dried (MgSO₄), filtered and evaporated to dryness
10 then triturated with diethyl ether to give a yellow crystalline solid which was dried *in vacuo* at 50°C. to give N-cyclopropylmethyl-5-methythio-2-nitrobenzamide. Mp 134°C.

15 **2-Amino-N-cyclopropylmethyl-5-methylthiobenzamide.**
N-Cyclopropylmethyl-5-methythio-2-nitrobenzamide (15.08 g, 0.057 mol) was suspended together with Raney Nickel (3.4 g) in methanol (250 ml) and hydrogenated at 60 psi and room temperature for 24
20 hr. The Raney Nickel was then isolated by filtration through celite, the filtrate evaporated to dryness and the residue triturated with diethyl ether to give 2-amino-N-cyclopropylmethyl-5-methylthiobenzamide as a cream solid. Mp 124°C.

N-(1-methylethyl)-4-methylthio-2-nitrobenzamide.

A solution of 4-methylthio-2-nitrobenzoic acid
(3.07 g, 0.01439 mol) [Lit. Ref. DE 2421541],
5 isopropylamine (1.47 ml, 0.01728 mol) and pyridine
(100ml) was cooled in an ice bath. Silicon
tetrachloride (2.01 ml, 0.01728 mol) was added
dropwise under nitrogen over 15 mins. After
stirring at room temperature for 2 hr the solution
10 was refluxed for 7 hr, then allowed to cool to room
temperature. The solution was added to water and
concentrated in vacuo. The precipitate was
dissolved in dichloromethane and washed twice with
1N hydrochloric acid (150ml), dried and
15 concentrated in vacuo to afford 2.82 g of amorphous
yellow solid. δ (^1H NMR, CDCl_3 , ppm) : 1.10 (6H, d),
2.50 (3H, s), 4.2 (1H, m), 5.50 (1H, s), 7.35 (2H,
m), 7.75 (1H, s).

20 **N-[1-(2,2-Dimethoxyethyl)]-4-methylsulphonyl-2-nitroaniline**

To a stirred solution of 2-fluoro-5-methylsulphonyl-1-nitrobenzene (3.75 g, 0.01711 mol) and sodium bicarbonate (1.58 g, 0.01882 mol)

in DMF (80 ml) was added amino acetaldehyde dimethyl acetal (1.85 ml, 0.01711 mol). The solution was allowed to stir at room temperature for 30 mins. After the addition of water (130 ml) the product was extracted with ethyl acetate (3 x 75 ml) and the organic fractions collected and washed with water (3 x 75 ml). The organic fractions were dried (MgSO_4), filtered and concentrated *in vacuo* to afford an amorphous yellow solid.

δ (^1H NMR, CDCl_3 , ppm) : 3.00 (3H, s), 3.35 (2H, d), 3.45 (6H, s), 4.60 (1H, t), 6.7 (1H, d), 7.20 (1H, d), 7.40 (1H, dd).

N-(4-Methylthiophenyl)-2,2-dimethylmalonamic acid

Thionyl chloride (8.15 g, 5 ml, 0.069 mol) was added to a stirred solution of 2,2-dimethylmalonic acid (7.26 g, 0.055 mol) in dry THF (55 ml). The mixture was heated under reflux for 3 hr. The reaction mixture was cooled to room temperature and 4-methylthioaniline (15.3 g, 0.11 mol) in THF (30 ml) was then added dropwise over 30 mins

to the solution. The mixture was stirred at room temperature for 2 hr. The reaction mixture was then concentrated in vacuo and then treated with hydrochloric acid (2N, 100 ml). The product was extracted with ethyl acetate (2 x 100 ml). The organic extracts were combined, then washed with water (100 ml) and saturated sodium hydrogen carbonate solution (5 x 80 ml). The organic layer was then acidified with hydrochloric acid (5N, 250 ml) and the resultant white crystalline precipitate was collected by filtration to afford N-(4-methylthiophenyl)-2,2-dimethylmalonamic acid. mp 130-132°C.

15

N-(4-Ethylsulfonylphenyl)-N'-(1-methylethyl)sulfamide

(1-Methylethyl)sulfamoyl chloride (6.63 g, 0.034 mol) was added dropwise to a solution of 4-(ethylsulfonyl)benzene amine (6 g, 0.032 mol) and triethylamine (4.87 ml, 0.035 mol) in dry dichloromethane (100 ml) at 0°C. under a nitrogen atmosphere. After addition, the resultant mixture was allowed to warm to room temperature and was

20

stirred for 6 hr. The reaction mixture was then washed with water (2 x 50 ml). The organic extracts were combined, dried (MgSO₄) and concentrated in vacuo to yield N-(4-ethylsulfonylphenyl)-N'-(1-methylethyl)sulfamide as a white solid. δ (¹H NMR, DMSO, ppm) : 1.05 (6H, d), 1.10 (3H, t), 3.25 (2H, q), 3.40 (1H, m), 7.40 (2H, d), 7.80 (3H, m).

Similarly prepared were
N-(4-Methylthiophenyl)-N'-(1-methylethyl)sulfamide
(Prepared from 4-(methylthio)benzene amine).

δ (¹H NMR, DMSO, ppm) : 0.8 (6H, d), 2.3 (3H, s), 3.2 (1H, m), 3.35 (1H, s), 6.9-7.1 (4H, m), 9.5 (1H, s). M.P. 65-68°C.

N-(4-Acetylphenyl)-N'-(1-methylethyl)sulfamide
(Prepared from 4-aminoacetophenone)
 δ (¹H NMR, CDCl₃, ppm) : 1.1 (6H, d), 2.5 (3H, s), 3.5 (1H, m), 4.4 (1H, d), 6.80 (1H, s), 7.10 (2H, d), 7.90 (2H, d).

Ethyl 4-(1-methylethylsulfamoylamino)benzoate
(Prepared from ethyl 4-aminobenzoate)

Mp 146°C.

3,4-Dihydro-6-(ethylsulfonyl)-3-(1-methylethyl)-1H-
2,1,3-benzothiadiazone-2,2-dioxide

5

N-(4-Ethylsulfonylphenyl)-N'-(1-methylethyl)sulfamide (5 g, 0.016 mol) was dissolved in dry dichloromethane (150 ml) and methanesulphonic acid (18.87 ml, 0.303 mol). The solution was cooled at 0°C. before the addition of trioxan (0.480 g, 0.005 mol) in dichloromethane (15 ml). After stirring at 0°C. for 1 hr, the reaction mixture was poured onto ice-water (250 ml), the layers separated, dried (MgSO₄) and concentrated in vacuo to yield 3,4-dihydro-6-(ethylsulfonyl)-3-(1-methylethyl)-1H-2,1,3-benzothiadiazone-2,2-dioxide as a white solid. δ (¹H NMR, DMSO, ppm) : 1.10 (9H, m), 3.30 (2H, q), 4.10 (1H, m), 4.80 (2H, s), 6.95 (1H, d), 7.75 (1H, dd), 7.80 (1H, d).

20

Prepared similarly were

Ethyl 3,4-dihydro-2,2-dioxo-3-(1-methylethyl)-1H-
2,1,3-benzothiadiazone-6-carboxylate

(Prepared from ethyl 4-(1-methylethylsulfamoylamino)benzoate)

Mp 156°C.

5 **6-Acetyl-3,4-dihydro-3-(1-methylethyl)-1H-2,1,3-benzothiadiazine-2,2-dioxide**

(Prepared from N-(4-acetylphenyl)-N'-(1-methylethyl)sulfamide)

10 δ (^1H NMR, CDCl_3 , ppm) : 1.0 (6H, d), 2.40 (3H, s),
4.00 (1H, m), 4.5 (2H, s) 6.55 (1H, d), 6.90 (1H, s), 7.60 (2H, m).

3,4-Dihydro-3-(1-methylethyl)-6-methylthio-1H-2,1,3-benzothiadiazine-2,2-dioxide

15 (Prepared from N-(4-methylthiophenyl)-N'-(1-methylethyl)sulfamide.

δ (^1H NMR, DMSO, ppm) : 0.9 (6H, d), 2.3 (3H, s),
3.9 (1H, m), 4.5 (2H, s), 6.6 (1H, d), 7.0 (2H, m),
10.1 (1H, s).

20

3,4-Dihydro-3-(1-methylethyl)-6-(methylsulfonyl)-1H-2,1,3-benzothiadiazine-2,2-dioxide

A solution of OXONE® (potassium peroxymonosulfate) (5.65 g, 0.0092 mol) in water was added to a solution of 3,4-dihydro-3-(1-methylethyl)-6-(methylthio)-1H-2,1,3-benzothiadiazine-2,2-dioxide (1 g, 0.0037 mol) in acetone/water (25 ml/2.5 ml) stirring at room temperature. After 30 mins, water (25 ml) and ethyl acetate (50 ml) were added to the mixture. The two layers were separated and the organic layer was then dried (MgSO₄) and concentrated in vacuo to afford 3,4-dihydro-3-(1-methylethyl)-6-(methylsulfonyl)-1H-2,1,3-benzothiadiazine-2,2-dioxide as a pale yellow solid. δ (¹H NMR, CDCl₃, 300MHz, ppm) : 1.0 (3H, d), 2.9 (3H, s), 4.1 (1H, m), 4.6 (2H, s), 6.8 (1H, d), 7.6 (2H, m), 9.9 (1H, s).

3-Cyclopropylmethyl-6-methylthio-3,4-dihydro-1H-2,1,3-benzothiadiazine-2,2-dioxide.

2-Amino-N-cyclopropylmethyl-5-methylthiobenzamide (10.96 g, 0.0464 mol) was dissolved in dry toluene (175 ml) in a 3 necked round bottomed flask equipped with a mechanical stirrer and a pressure equalising dropping funnel and cooled to 0°C. in an ice-water cooling bath. The pressure equalising

dropping funnel was charged with toluene (45 ml) and sodium bis(2-methoxyethoxy)aluminium hydride (65 wt % in toluene, 45 ml, 0.1398 mol) and added dropwise to the reaction mixture. The reaction mixture was then warmed to room temperature, heated under reflux during 5 hr, and then cooled and poured into ice-water. The resulting two phase mixture was filtered through a celite pad to remove alumina. The aqueous phase was further extracted with toluene, the combined toluene extract was washed with water, brine, then dried (MgSO_4), filtered and the filtrate evaporated to an oily residue, which was dissolved in diethyl ether and extracted (3 x) with hydrochloric acid (2M). The combined acidic extracts were washed with diethyl ether and then made basic with sodium hydroxide solution (2M) in the presence of diethyl ether. The ether layer was then separated washed with water, brine, dried (MgSO_4), filtered and evaporated to dryness to give an oil (9.17 g, 0.0412 mol) which was dissolved in diglyme (34 ml) and added to a magnetically stirred hot solution of sulphamide (4.7 g, 0.0474 mol) in diglyme (24 ml). The solution was stirred in an oil bath at 155-160°C.

for 3 hr. The cooled solution was poured into water
, the pH was adjusted to pH1 with 2M hydrochloric
acid. The mixture was then triturated with ethyl
acetate (2 x). The combined organic phase was
5 washed with water (2x), brine, 0.1M hydrochloric
acid and water again, dried over magnesium
sulphate, filtered and the solvent removed to give
an oil. This was chromatographed on flash silica
(eluent ethyl acetate/ hexane, 1:3) to give a waxy
10 solid. Mp ~97°C.

**3,4-Dihydro-3-(1-methylethyl)-7-(methylsulfonyl)-
1H-2,1,3-benzothiadiazine-2,2-dioxide.**

N-(1-Methylethyl)-4-methylthio-2-nitrobenzamide
15 (2.76 g, 0.01085 mol) and tin (II) chloride (7.35
g, 0.03256 mol) in EtOH (150ml) were stirred at
reflux under nitrogen for 4 hr. The reaction was
concentrated *in vacuo* and to the pale yellow oil
was added water (100 ml) and 50% NaOH (20 ml). The
20 solution was extracted twice with ethyl acetate
(150 ml), dried over MgSO₄ and concentrated *in
vacuo*. Column chromatography (eluent 50% ethyl
acetate/hexane) afforded 1.84 g of white amorphous
solid (76% yield). This solid (1.53 g, 0.00682mol)

in dry THF (25 ml) was added to a suspension of lithium aluminium hydride (0.78 g, 0.02046 mol) in dry THF (75 ml) under nitrogen at 0°C. This solution was heated at reflux with stirring for 24 hr. The reaction was allowed to cool and 50% NaOH was added dropwise with stirring and cooling to the solution until the effervescence ceased. The reaction was filtered through celite and concentrated *in vacuo*. Column chromatography afforded a pale yellow crystalline solid (0.90 g, 63% yield). This solid (0.90 g, 0.00428 mol) in pyridine (25 ml) was then added to a stirred solution of sulfamide (0.45 g, 0.00471 mol) in pyridine (75 ml) held at reflux. After heating under reflux for 15 hr the solution was concentrated *in vacuo* and to the oil was added ethyl acetate (100 ml). After washing twice with water (50 ml) and 2N HCl (50 ml) the solution was dried over MgSO₄ and concentrated *in vacuo* to afford 3,4-dihydro-3-(1-methylethyl)-7-(methylthio)-1H-2,1,3-benzothiadiazine-2,2-dioxide as a pink amorphous solid.

δ (¹H NMR, CDCl₃, ppm) : 1.10 (6H, d), 2.50 (3H, s), 4.10 (1H, m), 4.60 (2H, s), 6.50 (1H, d), 6.95 (1H, dd), 7.00 (1H, d).

3,4-Dihydro-6-hydroxymethyl-3-(1-methylethyl)-1H-
2,1,3-benzothiadiazine-2,2-dioxide.

Lithium aluminium hydride (0.4 g, 0.00105 mol) was
5 added portionwise to a suspension of methyl 3,4-
dihydro-3-(1-methylethyl)-1H-2,1,3-
benzothiadiazine-2,2-dioxide-6-carboxylate (2.5 g,
0.0087 mol.) in THF (30 ml) at 0°C., under argon.
The reaction was then warmed to room temperature
10 for 15 hr, cooled to 0°C. and treated with water (9
ml) followed by 15% aqueous sodium hydroxide
solution (9 ml), and then water (27 ml). After
stirring for 1 hr the mixture is filtered through
celite, the celite washed several times with 15%
15 aqueous sodium hydroxide solution. The aqueous
phase was adjusted to pH 4 with hydrochloric acid
(3M), and extracted with dichloromethane, the
dichloromethane extracts dried (Na₂SO₄) and
evaporated to dryness yielding 3,4-dihydro-6-
20 hydroxymethyl-3-(1-methylethyl)-1H-2,1,3-
benzothiadiazine-2,2-dioxide. ¹H-NMR, CDCl₃, 300 Mz,
δ: 7.13-7.09 (2H, m), 6.86 (NH, s), 6.60 (1H, d),
4.59 (4H, s), 4.14 (1H, m), 1.10 (6H, d).

6-t-Butyldimethylsiloxymethyl-3,4-dihydro-3-(1-methylethyl)-1H-2,1,3-benzothiadiazine-2,2-dioxide.

A suspension of 3,4-dihydro-6-hydroxymethyl-3-(1-methylethyl)-1H-2,1,3-benzothiadiazine-2,2-dioxide
5 (2.2 g, 0.0087 mol) and imidazole (0.680 g, 0.0099 mol) in DMF (13 ml) was treated at 0°C., under argon with a solution of t-butyldimethylsilyl chloride (1.5 g, 0.0099 mol) in DMF (5 ml). After the addition, the reaction was stirred at room
10 temperature for 3 hr. The reaction mixture was then poured over water and extracted with diethyl ether (3 x). The organic phase was washed with water, dried (Na₂SO₄) and evaporated to dryness to yield a solid (3.2 g) which was triturated with hexane and
15 then isolated by filtration to give 6-t-butyldimethylsiloxymethyl-3,4-dihydro-3-(1-methylethyl)-1H-2,1,3-benzothiadiazine-2,2-dioxide as a white solid. ¹H-NMR (CDCl₃, 300 Mz), δ: 7.14-7.02 (2H, m), 6.62 (1H, d), 6.36 (NH, s), 4.64
20 (2H, s), 4.58 (2H, s), 4.16 (1H, m), 1.11 (6H, d), 0.90 (9H, s), 0.07 (6H, s).

3,3-Dimethyl-6-methylthio-2,4(1H,3H)-quinolinedione

Phosphorus pentoxide (4.49 g, 0.032 mol) was added to a stirred solution of N-(4-methylthiophenyl)-2,2-dimethylmalonamic acid (5.0 g, 0.020 mol) in methanesulfonic acid (35 ml). The reaction mixture was warmed to 70°C. and stirred for 90 mins. The product mixture was then cooled to room temperature and poured over ice. The product was extracted with ethyl acetate (2 x 200 ml). The organic extracts were combined, washed with water (200 ml), saturated sodium hydrogen carbonate solution (200 ml), dried (MgSO₄) and concentrated *in vacuo* to give 3,3-dimethyl-6-methylthio-2,4(1H,3H)-quinolinedione as a yellow solid. Mp 152°C.

3,4-Dihydro-3,3-dimethyl-6-methylthio-2(1H)-quinolinone

Triethylsilane (34.75 ml, 49.1 g, 0.042 mol) was added dropwise to a stirred solution of 3,3-dimethyl-6-methylthio-2,4(1H,3H)-quinolinedione (12.79 g, 0.054 mol) in trifluoroacetic acid (520 ml) under nitrogen at 60°C. The reaction was then allowed to cool slowly to room temperature and was stirred for 16 hr. The solvent was then evaporated *in vacuo* to afford a yellow residue. The residue

was then poured into saturated potassium carbonate solution (200 ml). The product was extracted with ethyl acetate (3 x 150 ml). The organic extracts were combined, washed with water (200 ml), dried and concentrated in vacuo to afford 3,4-dihydro-3,3-dimethyl-6-methylthio-2(1H)-quinolinone as a yellow solid. Mp 154°C.

5-Bromo-3,3-dimethyl-1,3-dihydro-2H-indol-2-one.
3,3-Dimethyl-1,3-dihydro-2H-indol-2-one (1.12 g, 0.00695 mol) was dissolved in chloroform and stirred at room temperature under nitrogen. Bromine (1.12 g) was added and the mixture was heated under reflux until HBr evolution ceased and the bromine colour was discharged from the solution. The solution was washed with sodium metabisulphite solution and sodium hydrogen carbonate solution, dried (MgSO₄), filtered and concentrated to dry under reduced pressure to give 5-bromo-3,3-dimethyl-1,3-dihydro-2H-indol-2-one as a yellow solid. ¹H NMR (CDCl₃) 1.39 (6H s), 6.8 (1H d), 7.3 (2H m), 7.9 (1H broad).

1,3-Dihydro-1-[1-(2,2-dimethoxyethyl)]-5-methylsulphonyl-2,1,3-benzothiadiazole-2,2-dioxide
N-[1-(2,2-Dimethoxyethyl)]-4-methylsulphonyl-2-nitroaniline (4.68 g, 0.01538 mol) was dissolved

in methanol (100 ml) containing 10% palladium on charcoal (0.55 g) and hydrogenated at 70 psi for 20 mins. After removal of the catalyst, the solution was concentrated *in vacuo* to afford a pale pink amorphous solid (4.22 g, 100% yield). This compound (3.96 g, 0.01443 mol) in pyridine (50 ml) was added slowly to a refluxing solution of sulphamide (1.53 g) in pyridine (200 ml) and the reaction heated for a further 15hr. The reaction was cooled to room temperature, water added (100 ml) and the product extracted with ethyl acetate (3 x 70 ml). The organic fractions were collected, washed with water (150 ml) and 2N hydrochloric acid solution (2 x 100 ml). The organic layer was dried (MgSO₄) filtered and concentrated *in vacuo* to afford the product.

δ (¹H NMR, CDCl₃, ppm) : 3.00 (3H, s), 3.45 (6H, s), 3.80 (2H, d), 4.70 (1H, t), 7.1 (1H, d), 7.40 (1H, d), 7.60 (1H, dd).

1,3-Dihydro-1-[1-(2,2-dimethoxyethyl)]-3-methyl-5-methylsulphonyl-2,1,3-benzothiadiazole-2,2-dioxide
To a stirred solution of 1,3-dihydro-1-[1-(2,2-dimethoxyethyl)]-5-methylsulphonyl-2,1,3-

benzothiadiazole-2,2-dioxide (2.82 g, 0.00838 mol)
in DMF (100 ml) was added portionwise sodium
hydride (0.67 g, 0.01677 mol; 60% dispersion in
oil) and allowed to stir at room temperature for 3
5 hr. To this solution was added iodomethane (0.63
ml, 0.01006 mol) and the resultant mixture was
heated at 60°C. overnight. The reaction was allowed
to cool to room temperature and water (150 ml)
added. The product was extracted with ethyl acetate
10 (2 x 100 ml) and the combined organic fractions
washed with saturated sodium hydrogen carbonate
solution (2 x 100 ml) and water (2 x 100 ml). The
organic extracts were dried (MgSO₄) filtered and
concentrated *in vacuo* to afford title product after
15 chromatography.

δ (¹H NMR, CDCl₃, ppm) : 3.00 (3H, s), 3.40 (3H, s),
3.50 (6H, s), 3.90 (2H, d), 4.7 (1H, t), 7.10 (1H,
d), 7.30 (1H, s) 7.6 (1H, dd).

20 **3,4-Dihydro-3,3-dimethyl-1-(2-hydroxyethyl)-6-
methylthio-2(1H)-quinolinone.**

Sodium hydride (0.558 g at 60% dispersion, 0.015
mol) was added in portions to a stirred solution of
3,4-dihydro-3,3-dimethyl-6-methylthio-2(1H)-

quinolinone (2.5 g, 0.0113 mol) in dry DMF (12 ml) at 0°C. under nitrogen. The mixture was then allowed to warm to room temperature and stirred for 40 mins before 2-(2-chloroethoxy)-tetrahydropyran (2.5 ml, 2.79 g, 0.017 mol) was added. After addition, the resultant mixture was warmed to 70°C. and was stirred for 12 hr. The mixture was then poured into diethyl ether (100 ml), washed with hydrochloric acid (1M, 3 x 50 ml), washed with water, dried (MgSO₄) and the filtrate evaporated in vacuo to give an oil (5.369 g). The residue was immediately dissolved in methanol (30 ml) and treated with p-toluenesulfonic acid (0.25 g) and stirred at room temperature for 2 hr. The methanol was then evaporated in vacuo and the residue washed with sodium hydrogen carbonate solution, dried (MgSO₄), filtered and the solvent evaporated in vacuo to give 3,4-dihydro-3,3-dimethyl-1-(2-hydroxyethyl)-6-methylthio-2(1H)-quinolinone. δ (¹H NMR, CDCl₃, ppm) : 7.3 (1H, dd), 7.2 (1H, d), 7.1 (1H, d), 4.2 (2H, t), 4.0 (2H, m), 2.9 (2H, s), 2.6 (3H, s), 1.8 (1H, OH), 1.4 (6H, s).

3,4-Dihydro-3-(1-methylethyl)-6-methylthio-1-(prop-2-en-1-yl)-1H-2,1,3-benzothiadiazine-2,2-dioxide.

3,4-Dihydro-3-(1-methylethyl)-6-methylthio-1H-2,1,3-benzothiadiazine-2,2-dioxide (10 g, 0.0367 mol) was added to a suspension of sodium hydride (1.61g, 60% dispersion) in dry dimethylformamide (200 ml) at room temperature under a nitrogen atmosphere. The pale grey suspension was stirred for ten mins, and then allyl bromide (3.49 ml, 0.0404 mol) was added in one portion. The reaction mixture was stirred at 80°C. for 3 hr. The mixture was then concentrated *in vacuo* to yield a brown residue. The residue was dissolved in ethyl acetate (50 ml) and washed with water (2 x 50 ml). The organic layer was then dried (MgSO₄) and concentrated *in vacuo* to afford 3,4-dihydro-3-(1-methylethyl)-6-methylthio-1-(prop-2-en-1-yl)-1H-2,1,3-benzothiadiazine-2,2-dioxide. δ (¹H NMR, DMSO, ppm) : 1.1 (6H, d), 2.5 (3H, s), 4.1 (1H, m), 4.5 (2H, d), 4.7 (2H, s), 5.3 (1H, dd), 5.4 (1H, dd), 6.0 (1H, m), 7.0 (1H, d), 7.3 (2H, m).

[3,4-Dihydro-2,2-dioxido-3-(1-methylethyl)-6-methylsulfonyl-1H-2,1,3-benzothiadiazin-1-yl]ethanal.

3,4-Dihydro-3-(1-methylethyl)-6-methylthio-1-(prop-
5 2-en-1-yl)-1H-2,1,3-benzothiadiazine-2,2-dioxide
(10 g, 0.032 mol) was dissolved in dioxan (100 ml)
and water (20 ml). Osmium tetroxide (2 crystals)
was added to the solution and the mixture was
stirred for five mins at room temperature, before
10 the addition of sodium periodate (34.28g, 0.160
mol) dissolved in water (25 ml). After stirring at
ambient temperature for 14 hr, the reaction mixture
was filtered through celite. The filtrate was then
concentrated *in vacuo* to yield an oil. The oil was
15 dissolved in ethyl acetate (100 ml) and washed with
water (2 x 50 ml). The organic layer was then
dried and concentrated *in vacuo* to afford [3,4-
dihydro-2,2-dioxide-3-(1-methylethyl)-6-
methylsulfonyl-1H-2,1,3-benzothiadiazin-1-
20 yl]ethanal as a yellow solid. δ (^1H NMR, DMSO, ppm)
: 1.1 (6H, d), 3.2 (3H, s), 4.0 (1H, m), 4.8 (2H,
s), 4.9 (2H, s), 7.0 (1H, d), 7.7 (1H, dd), 7.8
(1H, d), 9.6 (1H, s).

[1,3-Dihydro-2,2-dioxido-3-methyl-5-methylsulphonyl-2,1,3-benzothiadiazol-1-yl]ethanal

1,3-Dihydro-1-[1-(2,2-dimethoxyethyl)]-3-methyl-5-methylsulphonyl-2,1,3-benzothiadiazole-2,2-dioxide

5 (1.4 g, 0.004 mol) and 20% HCl (20 ml) in acetone (15 ml) were allowed to stir at room temperature overnight. Further 20% HCl (10 ml) was added and the solution stirred for 6 hr. The reaction was neutralised with saturated sodium hydrogen
10 carbonate solution and the product extracted with ethyl acetate (3 x 100 ml). The organic fractions were dried (MgSO₄) and concentrated *in vacuo* to afford the product.

15 δ (¹H NMR, CDCl₃, ppm) : 3.00 (3H, s), 3.40 (3H, s), 4.60 (2H, s), 6.70 (1H, d), 7.35 (1H, d) 7.6 (1H, dd), 9.75 (1H, s)

1-(2-Chloroethyl)-3,4-dihydro-3-(1-methylethyl)-6-methylthio-1H-2,1,3-benzothiadiazine-2,2-dioxide.

20 To a 250 ml 3 necked flask equipped thermometer, pressure equalised dropping funnel; nitrogen bubbler and magnetic stirrer bar was added 60% sodium hydride (1.77 g, 1.062 g, 0.04425 mol,) hexane washed, to dry DMF (75 ml). To this stirred

suspension was added dropwise a solution of 3,4-dihydro-3-(1-methylethyl)-6-methylthio-1H-2,1,3-benzothiadiazine-2,2-dioxide (10.0 g, 0.0368mol) in dry DMF (75 ml) (slight exotherm). The suspension
5 was stirred under nitrogen for 2 hr until hydrogen evolution ceased. 1-Bromo-2-chloroethane (6.33 g, 3.77 ml, 0.04425 mol) was added dropwise and the reaction mixture allowed to stir at room temperature under nitrogen overnight. The reaction
10 mixture was poured onto ice-water (800 ml) with stirring for 1 hr, filtered and washed with water (200 ml) to leave a white solid which was dried in vacuo at 50°C. to give a solid. Mp 74-75°C.

15 Similarly prepared were
Ethyl 1-(2-chloroethyl)-3,4-dihydro-3-(1-methylethyl)-1H-2,1,3-benzothiadiazine-2,2-dioxide-6-carboxylate.

(Prepared from ethyl 3,4-dihydro-3-(1-methylethyl)-
20 1H-2,1,3-benzothiadiazine-2,2-dioxide-6-carboxylate)
Mp 96°C.

6-t-Butyldimethylsiloxymethyl-1-(2-chloroethyl)-
3,4-dihydro-3-(1-methylethyl)-1H-2,1,3-
benzothiadiazine-2,2-dioxide.

(Prepared from 6-t-butyldimethylsiloxymethyl-3,4-
5 dihydro-3-(1-methylethyl)-1H-2,1,3-
benzothiadiazine-2,2-dioxide)

¹H-NMR (CDCl₃, 300 Mz), δ: 7.25-7.15 (2H, m), 7.03
(NH, s), 6.92 (1H, d), 4.66 (2H, s), 4.54 (2H, s),
4.16 (1H, h), 4.02 (2H, t), 3.74 (2H, t), 1.13 (6H,
10 d), 0.92 (9H, s), 0.08 (6H, s).

6-Acetyl-1-(2-chloroethyl)-3,4-dihydro-3-(1-
methylethyl)-1H-2,1,3-benzothiadiazine-2,2-dioxide.

(Prepared from 6-acetyl-3,4-dihydro-3-(1-
15 methylethyl)-1H-2,1,3-benzothiadiazine-2,2-dioxide)
δ (¹H NMR, CDCl₃, ppm) : 0.9 (6H, d), 2.60 (3H, s),
3.65 (2H, t), 3.90 (1H, m), 4.00 (2H, t) 4.60 (2H,
s), 7.00 (1H, d), 7.70 (2H, m).

20 1-(2-Chloroethyl)-3,4-dihydro-6-(ethylsulfonyl)-3-
(1-methylethyl)-1H-2,1,3-benzothiadiazine-2,2-
dioxide.

(Prepared from 3,4-dihydro-6-(ethylsulfonyl)-3-(1-
methylethyl)-1H-2,1,3-benzothiadiazine-2,2-dioxide)

δ (^1H NMR, DMSO, ppm) : 1.00 (9H, m), 3.10 (2H, q), 3.70 (2H, t), 3.90 (1H, m), 4.10 (2H, t), 4.70 (2H, s), 7.20 (1H, d), 7.60 (2H, m).

5 1-(2-Chloroethyl)-3,4-dihydro-3-(1-methylethyl)-7-(methylthio)-1H-2,1,3-benzothiadiazine-2,2-dioxide.
(Prepared from 3,4-dihydro-3-(1-methylethyl)-7-(methylthio)-1H-2,1,3-benzothiadiazine-2,2-dioxide).

10 δ (^1H NMR, DMSO, ppm) : 1.20 (6H, d), 2.50 (3H, s), 3.80 (2H, t), 4.1 (3H, m), 4.55 (2H, s), 6.9 (3H, m).

15 1-(2-Chloroethyl)-3,4-dihydro-3-(1-methylethyl)-1H-2,1,3-benzothiadiazine-2,2-dioxide-6-carboxamide.

Ethyl 1-(2-chloroethyl)-3,4-dihydro-3-(1-methylethyl)-1H-2,1,3-benzothiadiazine-2,2-dioxide-6-carboxylate (3.96 g, 0.01327mol) was dissolved in dry DMF (20 ml) and to this solution, with
20 stirring, was added 60% sodium hydride oil dispersion (0.6 g, 0.0158 mol) in portions. This solution was stirred for 30 mins then cooled to 0-5°C. in an ice-bath. To this solution was added 1-bromo-2-chloroethane (2.42 ml, 0.029 mol) and the

temperature was raised to 60°C. and maintained for 24 hrs. The solution was quenched in water, extracted with ethyl acetate (2 x) and the organic phase washed with water, brine and dried over magnesium sulphate. After filtering and removal of the solvent, the residue was triturated with hexane, filtered and dried. (4.11 g; 86% yield)

5 The above material (2.9 g, 0.008 mol) was dissolved in THF (50ml) and lithium hydroxide solution (12 ml, 0.024 mol) added. The stirred solution was heated under gentle reflux for 17 hrs and then, after removal of the solvent, the residue was dissolved in water and extracted with chloroform. After filtration through celite, the aqueous phase

10 was acidified with 2N HCl (15 ml; 0.03 mol). A white precipitate was filtered off, washed with water and dried. (2.48 g, 93% yield).

15 The above carboxylic acid (1.16 g, 0.0035 mol) was suspended in hexane (50ml) and to this was added thionyl chloride (3.0 ml, 0.035 mol) and 2 drops of

20 pyridine. The mixture was heated under reflux for 1 hr and then evaporated to dryness, azeotroping with hexane. The product was dissolved in dry THF (30 ml) and ammonia (0.88 g/ml) added slowly until

basic. After stirring for 30 mins the solution was evaporated to near dryness and partitioned between ethyl acetate and water. The organic phase was washed with water and brine, dried (MgSO_4), filtered and the solvent removed to produce a gum which on triturating with ether gave a solid, 1-(2-chloroethyl)-3,4-dihydro-3-(1-methylethyl)-1H-2,1,3-benzothiadiazine-2,2-dioxide-6-carboxamide. Mp 137 °C.

10

Similarly prepared was

1-(2-Chloroethyl)-3,4-dihydro-3-(1-methylethyl)-1H-2,1,3-benzothiadiazine-2,2-dioxide-6-N-methylcarboxamide.

15

(Prepared from ethyl 1-(2-chloroethyl)-3,4-dihydro-3-(1-methylethyl)-1H-2,1,3-benzothiadiazine-2,2-dioxide-6-carboxylate).

δ (^1H NMR, CDCl_3 , ppm) 7.6 (2H, m), 7.0 (1H, m), 6.1 (1H, NH), 4.1 (3H, m), 3.8 (2H, t), 3.0 (3H, db), 1.1 (6H, d).

20

1-(2-Chloroethyl)-3,4-dihydro-3-(1-methylethyl)-6-methylsulfinyl-1H-2,1,3-benzothiadiazine-2,2-dioxide.

3,4-Dihydro-3-(1-methylethyl)-6-methylthio-1H-2,1,3-benzothiadiazine-2,2-dioxide (10 g, 0.0299 mol) was dissolved in glacial acetic acid (100 ml) and sodium perborate (4.6 g, 0.0299 mol) added. The suspension was allowed to stir at room temperature under nitrogen for 18hr and then was poured into water (500 ml) and extracted with ethyl acetate (2 x 500 ml). The organic phase was washed with water (2 x 500 ml), saturated sodium hydrogen carbonate solution (500 ml), dried (MgSO₄), filtered and evaporated under reduced pressure to leave a pale yellow oil. After flash chromatography (eluting with ethyl acetate-hexane, then ethyl acetate), the product after removal of solvent crystallised on standing to give a solid.

δ (¹H NMR, CDCl₃, ppm) : 7.5 (2H, m), 7.0 (1H, d), 4.6 (2H, m), 4.2 (1H, m), 4.1 (2H, t), 2.7 (3H, s), 1.1 (6H, m).

Similarly prepared was
1-(2-Chloroethyl)-3-cyclopropylmethyl-6-methylsulphonyl-3,4-dihydro-1H-2,1,3-benzothiadiazine-2,2-dioxide. (Prepared from 3-

cyclopropylmethyl-3,4-dihydro-6-methylthio-1H-
2,1,3-benzothiadiazone-2,2-dioxide).

5 δ (^1H NMR, CDCl_3 , ppm) 7.4 (2H, m), 6.9 (1H, db),
4.6 (2H, s), 4.0 (2H, t), 3.6 (2H, t), 2.7 (2H, m),
2.5 (3H, s), 0.8 (1H, m), 0.4 (2H, m), 0.0 (2H, m).

1-(2-Chloroethyl)-3,3-dimethyl-6-methylthio-2(1H)-
quinolinone.

10 Methanesulfonyl chloride (1.05 ml, 1.56 g, 0.014
mol) was added to a solution of 3,4-dihydro-3,3-
dimethyl-1-(2-hydroxyethyl)-6-methylthio-2(1H)-
quinolinone (2.88 g, 0.011 mol) and triethylamine
(2.27 ml, 1.64 g, 0.016 mol) in dichloromethane (50
15 ml) at 0°C . under nitrogen and the resultant
mixture was stirred for 20 mins. Then the mixture
was allowed to warm to room temperature and stirred
for 20 hr. The reaction mixture was then washed
with water (2 x 20 ml), dried (MgSO_4), filtered and
concentrated in vacuo. The residue was then
20 dissolved in carbon tetrachloride (30 ml),
filtered and the solvent was evaporated in vacuo to
afford 1-(2-chloroethyl)-3,3-dimethyl-6-methylthio-
2(1H)-quinolinone as an oil which solidified on
standing.

δ (^1H NMR, CDCl_3 , ppm) : 7.3 (1H, dd), 7.2 (1H, d), 7.1 (1H, d), 4.4 (2H, t), 3.8 (2H, t), 2.9 (2H, s), 2.6 (3H, s), 1.3 (6H, s).

5 1-(2-Chloroethyl)-3,4-dihydro-3-(1-methylethyl)-6-methylsulfonyl-1H-2,1,3-benzothiadiazine-2,2-dioxide.

A 500 mL 3 necked flask equipped thermometer, pressure equalised dropping funnel, nitrogen
10 bubbler and magnetic stirrer bar was charged with 1-(2-chloroethyl)-3,4-dihydro-3-(1-methylethyl)-6-methylthio-1H-2,1,3-benzothiadiazine-2,2-dioxide (10.0 g, 0.0299 mol) and chloroform (200 ml). To this solution was added in one portion m-
15 chloroperbenzoic acid (20.6 g , ~4 equivalents, nominal purity 56-86 %), this resulted in an exotherm which raised the temperature from 20°C. to 50°C. This solution was then stirred for 15 mins, water (100 ml) was added then 2M sodium hydroxide
20 (100 ml). The organic layer was separated, washed again with 2M sodium hydroxide (100 ml), then water (100 ml) dried (MgSO_4), filtered and the filtrate evaporated under reduced pressure to leave a white-

cream foam, which was dried at 45°C. *in vacuo* to yield the product.

5 δ (¹H NMR, CDCl₃, ppm) : 7.8 (1H, d), 7.7 (1H, s),
7.1 (1H, d), 4.7 (2H, s), 4.2 (1H, m), 4.2 (2H, t),
3.0 (3H, s), 1.1 (6H, d).

Similarly prepared were

10 1-(2-Chloroethyl)-3,4-dihydro-3-(1-methylethyl)-7-(methylsulfonyl)-1H-2,1,3-benzothiadiazine-2,2-dioxide.

(Prepared from 1-(2-chloroethyl)-3,4-dihydro-3-(1-methylethyl)-7-(methylthio)-1H-2,1,3-benzothiadiazine-2,2-dioxide.

MW = 366 [M+H⁺ = 367]

15

1-(2-Chloroethyl)-3,4-dihydro-3,3-dimethyl-6-methylsulfonyl-2(1H)-quinolinone.

(Prepared from 1-(2-chloroethyl)-3,4-dihydro-3,3-dimethyl-6-methylthio-2(1H)-quinolinone.

20 δ (¹H NMR, CDCl₃, ppm) : 7.8 (1H, dd), 7.7 (1H, d), 7.1 (1H, d), 4.2 (2H, t), 3.6 (2H, t), 3.0 (3H, s), 2.8 (2H, s), 1.1 (6H, s).

1-(2-Chloroethyl)-1,3-dihydro-3,3-dimethyl-5-methylsulfinyl-2H-indol-2-one.

5-Bromo-3,3-dimethyl-1,3-dihydro-2H-indol-2-one (3.4 g, 0.0142 mol) was dissolved in freshly distilled tetrahydrofuran and cooled to -75°C. under nitrogen. n-Butyllithium in hexane (2.5M, 15 ml, 0.0375 mol) was added and the mixture was stirred at -70°C. for 1 hour. Dimethyl disulfide (2 ml, 1.692g, 0.0272 mol) was added and the mixture allowed to warm to room temperature. Aqueous ammonium chloride was added and the mixture was concentrated under reduced pressure, the resulting oil was taken up in ethyl acetate and dried (MgSO₄), filtered and concentrated under reduced pressure to give a white solid (3.5 g) This solid was dissolved in dimethylformamide and sodium hydride (0.6 g) was added and the mixture stirred for 20 mins at room temperature before 1-bromo-2-chloroethane (2.5 g, 0.0174 mol) was added and then the mixture warmed to 60°C. overnight. The reaction mixture was poured into aqueous ammonium chloride solution, extracted with ethyl acetate washed with water and dried. The solvent was reduced *in vacuo* and the resultant solution filtered through a silica pad to give an oil (4 g). This oil was dissolved in dichloromethane and m-chloroperbenzoic acid added portion-wise. The

reaction mixture in dichloromethane was then washed with sodium hydrogen carbonate solution, the dichloromethane solution dried, evaporated in vacuo and the residue chromatographed on silica eluting with ethyl acetate/hexane (3:2), then ethyl acetate/methanol (7:1) to give 1-(2-chloroethyl)-1,3-dihydro-3,3-dimethyl-5-methylsulfinyl-2H-indol-2-one. ¹H NMR (300 MHz, CDCl₃) δ 7.8, d (1H), 7.5, d d (1H), 7.0, d (1H), 4.1, t, (2H), 3.8, t, (2H), 2.8, s, (3H), 1.4, s, (6H).

Similarly prepared was

1-(2-Chloroethyl)-1,3-dihydro-3,3-dimethyl-5-methylsulfonyl-2H-indol-2-one

(Prepared from 5-Bromo-3,3-dimethyl-1,3-dihydro-2H-indol-2-one as for the synthesis of 1-(2-chloroethyl)-1,3-dihydro-3,3-dimethyl-5-methylsulfinyl-2H-indol-2-one but with the addition of excess of *m*-chloroperbenzoic acid).

¹H NMR (300 MHz, CDCl₃) δ 7.9, d db, (1H), 7.8, d (1H), 7.1, d d (1H), 4.1, m, (2H), 3.8, m, (2H), 3.0, (3H), 1.4, s, (6H).

2-Oxo-oxazolidine-3-sulfonic acid isopropyl-amide

To a 250 L glass lined reactor initially charged with dichloromethane (42 L) was added chlorosulfonyl isocyanate (4.5 kg, 31.8 moles) at room temperature and under a nitrogen atmosphere.

The reaction mixture was cooled to about 1° C. and a solution of 2-bromoethanol (4.00 kg, 1 eq.) in dichloromethane (14 L) was slowly added over 51 minutes in order to keep the reaction

5 temperature between 0 and 10° C. Stirring of the reaction mixture was continued at the same temperature for a minimum of 30 minutes. Progress of the reaction was monitored by ¹H-NMR. A mixture of isopropylamine (2.1 kg, 1.1 eq.) and

10 triethylamine (7.1 kg) in dichloromethane (28 L) was then added at such an addition rate that the reaction temperature was maintained between 0 and 10° C. The solution was heated up to room temperature. Aqueous hydrochloric acid (~0.2 N,

15 28.5 kg) was then added and the pH of the reaction mixture was adjusted to about 2 by addition of concentrated hydrochloric acid (450 ml in 2 portions). The reaction mixture was decanted and the separated organic layer washed with aqueous

20 hydrochloric acid (28.1 kg, ~0.05 N). The decanted and separated organic layer was washed with water (28 kg). To the decanted and separated organic layer, water (28 kg) was then added, and the reactor was placed under vacuum to distil the

25 maximum of dichloromethane while controlling the temperature below 25° C. (84.4 kg of distillate). The resulting suspension was stirred for a minimum

of 2 hours at room temperature, filtrated, rinsed twice with water (2 x 7 L) and dried under vacuum at about 50° C. during 16 hours to afford the 2-oxo-oxazolidine-3-sulfonic acid isopropyl-amide.

5

**1-Methylethylamino-1-sulfonic acid
(4-methanesulfonylphenyl)-amide**

A 100 L glass lined reactor was charged with
10 acetonitrile (17.8 kg) and 4-methylsulfonylaniline hydrochloride (3.36 kg, 16.2 moles) under stirring at room temperature. Triethylamine (4.5 kg) and 2-oxo-oxazolidine-3-sulfonic acid isopropyl-amide (3.70 kg, 1.1 eq.) were then added at the same
15 temperature. The reaction mixture was heated to reflux and stirred at the same temperature for a minimum of 6 hours. The solution was then slowly cooled to room temperature and kept agitated over night. Water was slowly added over 40 minutes and
20 the reactor was placed under vacuum to distil as much as possible of acetonitrile (27.8 kg of distillate) while maintaining the reaction temperature below 40° C. The suspension was cooled to room temperature and stirred for a minimum of
25 2 hours before filtering the product. The cake was

rinsed with water (16.2 kg) and dried under vacuum at about 50° C. for a minimum of 16 hours to yield the 1-methylethylamino-1-sulfonic acid (4-methanesulfonylphenyl)-amide.

5

EXAMPLES 1 TO 5

1- [2- [4- (6-Fluoro-1H-indol-3-yl) -3,6-dihydro-1(2H) -
10 pyridinyl] ethyl] -3,4-dihydro-3,3-dimethyl-6-
methylsulfonyl-2(1H)-quinolinone.

1- (2-Chloroethyl) -3,4-dihydro-3,3-dimethyl-6-
methylsulfonyl-2(1H)-quinolinone (1.0 g, 0.0032
mol), 6-fluoro-3- (1,2,3,6-tetrahydro-4-pyridinyl) -
15 1H-indole (0.684 g, 0.0032 mol), sodium iodide
(0.15g, 0.001 mol) and potassium carbonate (1.38 g,
0.010 mol) were suspended in acetonitrile (45 ml).
The reaction mixture was heated at reflux under
nitrogen for 20 hr. The product mixture was then
20 cooled to room temperature. The solvent was
evaporated in vacuo. The residue was dissolved in
ethyl acetate (50 ml) and washed with water (50
ml). The organic layer was then dried (MgSO₄),
filtered and concentrated in vacuo. The residue
25 was chromatographed to afford 1- [2- [4- (6-fluoro-1H-

indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]ethyl]-3,4-dihydro-3,3-dimethyl-6-methylsulfonyl-2(1H)-quinolinone as a yellow foam. δ (^1H NMR, DMSO, ppm)
: 1.28 (6H, s), 2.68 (2H, m), 3.14 (2H, s), 3.40
5 (3H, s), 3.55 (3H, br), 3.96 (1H, br), 4.06 (1H, br), 4.30 (1H, d), 4.60 (2H, t), 6.36 (1H, s), 7.11 (1H, dt), 7.35 (1H, dd), 7.78 (2H, m), 8.00 (3H, m), 11.56 (1H, s).

10 Similarly prepared were

1-[2-[4-(6-Fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]ethyl]-3,3-dimethyl-5-methylsulfinyl-1,3-dihydro-2H-indol-2-one. Mp 46-48°C.

15 1-[2-[4-(6,7-Difluoroindol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]ethyl]-3,3-dimethyl-5-methylsulfinyl-1,3-dihydro-2H-indol-2-one. Mp 173.5-175.5°C.

20 1-[2-[4-(6-Fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]ethyl]-3,3-dimethyl-5-methylsulfonyl-1,3-dihydro-2H-indol-2-one. Mp 95-98°C.

1- [2- [4- (6,7-Difluoro-1H-indol-3-yl) -3,6-dihydro-
1(2H)-pyridinyl]ethyl] -3,3-dimethyl-5-
methylsulfonyl-1,3-dihydro-2H-indol-2-one.

Mp 222-223°C.

5

EXAMPLES 6 TO 22

3,4-Dihydro-6-ethylsulfonyl-1- [2- [4- (6-fluoro-1H-
indol-3-yl) -3,6-dihydro-1(2H)-pyridinyl]ethyl] -3-
10 (1-methylethyl) -1H-2,1,3-benzothiadiazine-2,2-
dioxide.
1- (2-Chloroethyl) -3,4-dihydro-6- (ethylsulfonyl) -3-
(1-methylethyl) -1H-2,1,3-benzothiadiazine-2,2-
dioxide (1.03 g, 0.0027 mol), 6-fluoro-3- (1,2,3,6-
15 tetrahydro-4-pyridinyl) -1H-indole (0.706 g, 0.0033
mol), sodium iodide (0.408 g, 0.0027 mol) and
sodium bicarbonate (1.586 g, 0.015 mol) were
suspended in water (75 ml). The reaction mixture
was heated at reflux overnight. The product mixture
20 was then cooled to room temperature. The product
was extracted into ethyl acetate (3 x 50 ml). The
organic extracts were combined, washed with water
(150 ml), dried (MgSO₄) and concentrated *in vacuo* to
afford 3,4-dihydro-6-ethylsulfonyl-1- [2- [4- (6-

fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-
pyridinyl]ethyl]-3-(1-methylethyl)-1H-2,1,3-
benzothiadiazine-2,2-dioxide. δ (^1H NMR, DMSO, ppm)
: 1.10 (9H, m), 2.50 (2H, m), 2.80 (4H, m), 3.25
5 (4H, m), 4.10 (3H, m), 4.90 (2H, s), 6.10 (1H, s),
6.90 (1H, dt), 7.20 (1H, dd), 7.35 (1H, d), 7.40
(1H, d), 7.80 (3H, m), 11.20 (1H, s).

Similarly prepared were

6-Carboxamido-3,4-dihydro-1-[2-[4-(6-fluoro-1H-
10 indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]ethyl]-3-
(1-methylethyl)-1H-2,1,3-benzothiadiazine-2,2-
dioxide.

Mp 142°C.

15 3,4-Dihydro-1-[2-[4-(6-fluoro-1H-indol-3-yl)-3,6-
dihydro-1(2H)-pyridinyl]ethyl]-6-N-
methylcarboxamido-3-(1-methylethyl)-1H-2,1,3-
benzothiadiazine-2,2-dioxide.

δ (^1H NMR, DMSO, ppm) : 8.3 (1H, m), 7.7 (3H, m),
20 7.4 (1H, m), 7.3 (2H, db), 6.9 (1H, d db), 6.1 (1H,
m), 4.7 (2H, s), 4.0 (3H, m), 3.3 (4H, m), 2.8 (7H,
m), 1.0 (6H, db).

1- [2- [4- (6,7-Difluoro-1H-indol-3-yl) -1-piperidinyl]ethyl] -3,4-dihydro-3- (1-methylethyl) -6-methylsulfinyl-1H-2,1,3-benzothiadiazine-2,2-dioxide.

5 Mp 198.6-200.8°C.

1- [2- [4- (1H-Indol-3-yl) -3,6-dihydro-1(2H) -pyridinyl]ethyl] -3,4-dihydro-3- (1-methylethyl) -6-methylsulfinyl-1H-2,1,3-benzothiadiazine-2,2-dioxide.

10

δ (^1H NMR, DMSO, ppm) : 7.9 (1H, m), 7.7 (2H, m), 7.5 (2H, s), 7.4 (1H, m), 7.2 (3H, m), 6.2 (1H, m), 4.9 (2H, s), 4.1 (3H, m), 3.4 (4H, m) 2.7 (7H, m), 1.2 (6H, d).

15

6-Acetyl-3,4-dihydro-1- [2- [4- (6-fluoro-1H-indol-3-yl) -3,6-dihydro-1(2H) -pyridinyl]ethyl] -3- (1-methylethyl) -1H-2,1,3-benzothiadiazine-2,2-dioxide.

Mp 80-86°C.

20

1- [2- [4- (6-Fluoro-1H-indol-3-yl) -3,6-dihydro-1(2H) -pyridinyl]ethyl] -3,4-dihydro-3- (1-methylethyl) -6-methylsulfonyl-1H-2,1,3-benzothiadiazine-2,2-dioxide.

Mp 118-120°C.

5 1-[2-[4-(6-Fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-
pyridinyl]ethyl]-3,4-dihydro-3-(1-methylethyl)-6-
methylsulfinyl-1H-2,1,3-benzothiadiazine-2,2-
dioxide.

Mp 105-107°C.

10 1-[2-[4-(6-Fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-
pyridinyl]ethyl]-3,4-dihydro-3-(1-methylethyl)-6-
methylthio-1H-2,1,3-benzothiadiazine-2,2-dioxide.

Mp 80-8 °C.

15 1-[2-[4-(6-Fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-
pyridinyl]ethyl]-3,4-dihydro-3-(1-
cyclopropylmethyl)-6-methylsulfinyl-1H-2,1,3-
benzothiadiazine-2,2-dioxide.

Mp 134°C.

20 1-[2-[4-(5-Fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-
pyridinyl]ethyl]-3,4-dihydro-3-(1-methylethyl)-6-
methylsulfinyl-1H-2,1,3-benzothiadiazine-2,2-
dioxide.

δ (^1H NMR, DMSO, ppm) : 7.6 (2H, m), 7.5 (1H, dd),
7.4 (1H, s), 7.3 (1H, q), 7.2 (2H, d), 6.9 (1H,
m), 6.0 (1H, m), 4.8 (2H, s), 4.0 (3H, m), 3.2 (4H,
m), 2.7 (7H, m), 1.0 (6H, m).

5

1-[2-[4-(6-Fluoro-1H-indol-3-yl)-1-
piperidinyl]ethyl]-3,4-dihydro-3-(1-methylethyl)-6-
methylsulfinyl-1H-2,1,3-benzothiadiazine-2,2-
dioxide.

10

δ (^1H NMR, DMSO, ppm) : 7.5 (2H, m), 7.4 (1H, m),
7.2 (1H, s), 7.1 (1H, m), 7.0 (1H, s), 6.7 (1H, m),
4.6 (2H, s), 4.0 (1H, m), 3.8 (2H, t), 2.8 (3H, s),
2.9 (2H, m), 2.5 (2H, t), 2.1 (2H, t), 1.8 (2H, m),
1.6 (2H, m), 1.0 (6H, d).

15

1-[2-[4-(6-Fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-
pyridinyl]ethyl]-3,4-dihydro-3-(1-
cyclopropylmethyl)-6-methylsulfonyl-1H-2,1,3-
benzothiadiazine-2,2-dioxide.

20

δ (^1H NMR, DMSO, ppm) : 7.7 (3H, m), 7.2 (2H, m),
7.0 (1H, dd), 6.7 (1H, m), 6.0 (1H, m), 4.0 (2H,
m), 3.2 (2H, m), 3.0 (6H, m), 2.7 (2H, d) 2.5 (3H,
m), 0.9 (1H, m), 0.3 (2H, m), 0.0 (2H, m).

1-[2-[4-(6,7-Difluoro-1H-indol-3-yl)-3,6-dihydro-
1(2H)-pyridinyl]ethyl]-3,4-dihydro-3-(1-
cyclopropylmethyl)-6-methylsulfonyl-1H-2,1,3-
benzothiadiazine-2,2-dioxide.

5 δ (^1H NMR, DMSO, ppm) : 7.7 (3H, m), 7.4 (1H, dd),
7.3 (1H, m), 7.2 (1H, d), 6.9 (1H, m), 6.0 (1H, m),
4.8 (2H, s), 4.0 (2H, m), 3.2 (2H, m), 3.0 (6H, m),
2.7 (2H, d), 2.5 (2H, m), 0.9 (1H, m), 0.3 (2H, m),
0.0 (2H, m).

10

1-[2-[4-(6-Fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-
pyridinyl]ethyl]-3,4-dihydro-3-(1-methylethyl)-7-
methylsulfonyl-1H-2,1,3-benzothiadiazine-2,2-
dioxide.

15 δ (^1H NMR, DMSO, ppm) : 7.6 (1H, m), 7.5 (2H, m),
7.4 (1H, d), 7.2 (1H, m), 7.0 (1H, dd), 6.8 (1H,
m), 6.0 (1H, m), 4.6 (2H, s), 3.9 (3H, m), 3.1 (7H,
m), 2.8 (4H, d), 1.0 (6H, d).

20

1-[2-[4-(6,7-Difluoro-1H-indol-3-yl)-3,6-dihydro-
1(2H)-pyridinyl]ethyl]-3,4-dihydro-3-(1-
methylethyl)-6-methylsulfonyl-1H-2,1,3-
benzothiadiazine-2,2-dioxide.

δ (^1H NMR, DMSO, ppm) : 7.8 (2H, m), 7.6 (1H, m),
7.5 (1H, m), 7.3 (1H, d), 7.0 (1H, dd), 6.1 (1H,
m), 4.8 (2H, s), 4.0 (3H, m), 3.3 (2H, m), 3.2 (6H,
m), 2.7 (3H, m), 1.0 (6H, d).

5 1-[2-[4-(6-Fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-
pyridinyl]ethyl]-6-t-butyltrimethylsilyloxymethyl-3,4-
dihydro-3-(1-methylethyl)-1H-2,1,3-
benzothiadiazine-2,2-dioxide.

^1H -NMR (CDCl_3 , 300 Mz), δ : 8.15 (broad s, NH), 7.76
10 (dd, 1H), 7.20-6.84 (m, 6H), 6.14 (broad s, 1H),
4.65 (s, 2H), 4.57 (s, 2H), 4.13 (h, 1H), 3.98 (t,
2H), 3.30 (broad s, 2H), 2.87-2.79 (m, 4H), 2.58
(broad s, 2H), 1.10 (d, 6H), 0.90 (s, 9H), 0.09 (s,
6H).

15

EXAMPLE 23

1-[2-[4-(6-Fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-
pyridinyl]ethyl]-3,4-dihydro-3-(1-methylethyl)-6-
20 methylsulfonyl-1H-2,1,3-benzothiadiazine-2,2-
dioxide.

To a stirred solution of 3,4-dihydro-3-(1-
methylethyl)-6-methylsulfonyl-1H-2,1,3-
benzothiadiazine-2,2-dioxide (0.38 g, 0.00125 mol),

triphenylphosphine (0.39 g, 0.0015 mol) and 2-(4-(6-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl)ethanol (0.26 g, 0.0015 mol) in DMF (10 ml) at -5°C. was added dropwise under nitrogen

5 diethyl azodicarboxylate (0.24ml, 0.0015 mol). The reaction was stirred at -5°C. for 10 mins then allowed to warm to room temperature stirring for a further 20 mins. After the addition of ethyl acetate (30 ml) and water (20 ml), the organic

10 layer was washed with water (4 x 20 ml), the organics dried (MgSO₄) and concentrated *in vacuo* to afford 0.52 g of 1-[2-[4-(6-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]ethyl]-3,4-dihydro-3-(1-methylethyl)-6-methylsulfonyl-1H-2,1,3-

15 benzothiadiazine-2,2-dioxide as a yellow solid. Mp 118-120°C.

EXAMPLE 24

20 1-[2-[4-(6-Fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]ethyl]-3,4-dihydro-6-hydroxymethyl-3-(1-methylethyl)-1H-2,1,3-benzothiadiazine-2,2-dioxide. Tetrabutylammonium fluoride (2 ml, 0.002 mol, 1M in THF) was added to a suspension of 1-[2-[4-(6-

fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-
pyridinyl]ethyl]-6-t-butyldimethylsiloxymethyl-3,4-
dihydro-3-(1-methylethyl)-1H-2,1,3-
benzothiadiazine-2,2-dioxide (1.1 g, 0.0018 mol) in
5 THF (18 ml) under argon then stirred at room
temperature for 2 h, evaporated to dryness and
purified by flash chromatography using
dichlormethane/methanol (97:3) as eluent, to give
1-[2-[4-(6-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-
10 pyridinyl]ethyl]-3,4-dihydro-6-hydroxymethyl-3-(1-
methylethyl)-1H-2,1,3-benzothiadiazine-2,2-dioxide
as a pale yellow solid. Mp: 113-115°C. ¹H-NMR
(CDCl₃, 300 Mz), δ: 8.09 (NH, s), 7.76 (1H, dd),
7.22 (1H, d), 7.11 (1H, d), 7.08 (1H, s), 7.01 (1H,
15 dd), 6.98 (1H, d), 6.88 (1H, dt), 6.13 (1H, t),
3.29 (2H, s), 2.85-2.81 (4H, m), 2.58 (2H, s), 1.11
(6H, d).

EXAMPLE 25

20

1,3-Dihydro-1-[2-[4-(6-fluoro-1H-indol-3-yl)-3,6-
dihydro-1(2H)-pyridinyl]ethyl]-3-(1-methylethyl)-5-
(methylsulfonyl)-1H-2,1,3-benzothiadiazole-2,2-
dioxide.

Sodium triacetoxyborohydride (0.68 g, 0.00319 mol) was added portionwise to (1,3-dihydro-2,2-dioxido-3-methyl-5-methylsulphonyl-2,1,3-benzothiadiazol-1-yl)ethanal (0.97 g, 0.00319 mol) and 6-fluoro-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (0.69 g, 0.00319 mol) in dichloroethane (60 ml). To this mixture at room temperature was added portionwise 3 drops of acetic acid and the mixture stirred for 1.5 hr. The solution was then diluted with water (100 ml), neutralised with saturated sodium bicarbonate solution and extracted with ethyl acetate (2 x 70 ml). The organic extracts were washed with water (3 x 70 ml), dried (MgSO₄) filtered and concentrated *in vacuo*. Column chromatography on the residue afforded 1,3-dihydro-1-[2-[4-(6-fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]ethyl]-3-(1-methylethyl)-5-(methylsulfonyl)-1H-2,1,3-benzothiadiazole-2,2-dioxide.

¹H NMR (300 MHz, DMSO) δ, 7.85, (1H, dd), 7.6 (1H, m), 7.2 (1H, dd), 6.9, (1H, m), 6.2 (1H, m), 4.5 (2H, m), 4.1 (2H, m), 4.0 (1H, m), 3.8 (1H, m), 3.6 (2H, m), 3.4 (3H, s), 3.2 (3H, s), 2.8 (2H, m).

EXAMPLES 25 TO 30

Preparation of 1-[2-[4-(6-fluoro-1H-indol-3-yl)-1-piperidinyl]ethyl]-3,4-dihydro-3-(1-methylethyl)-6-methylsulfonyl-1H-2,1,3-benzothiadiazine-2,2-dioxide.

A vial was charged with a solution of [3,4-dihydro-2,2-dioxido-3-(1-methylethyl)-6-methylsulfonyl-1H-2,1,3-benzothiadiazin-1-yl]ethanal in methanol (0.12M, 0.5 ml) and a solution of 4-(6-fluoro-1H-indol-3-yl)-1-piperidine in acetic acid /methanol (1:4) (0.02M, 1 ml). The vial was capped and swirled at room temperature in air on an orbital shaker (100 rpm) for 1 hour. A solution of sodium cyanoborohydride in methanol (0.1M, 0.5 ml) was then added to the contents of the vial. The vial was recapped and agitation continued as before on the orbital shaker for 72h. The contents of the vial were then applied to a 500mg SCX ion exchange column pre-conditioned with methanol. The column was then washed with methanol (3 ml). The column was then treated with 2N ammonia in methanol (2 x 2.5 ml) to release the basic product. Solvent was then removed *in vacuo* to yield 1-[2-[4-(6-fluoro-

1H-indol-3-yl)-1-piperidinyl]ethyl]-3,4-dihydro-3-(1-methylethyl)-6-methylsulfonyl-1H-2,1,3-benzothiadiazone-2,2-dioxide as a pale yellow gum.

¹H NMR (300 MHz, CDCl₃) δ 7.9 (1H, s), 7.8 (1H, dd), 7.6 (1H, d), 7.5 (1H, dd), 7.1 (1H, d), 7.0 (1H, dd), 6.9 (1H, d), 6.8 (1H, t), 4.7 (2H, s), 4.2 (1H, t), 4.0 (2H, t), 3.1 (2H, d), 3.0 (3H, s), 2.7 (3H, m), 2.3 (2H, t), 1.8 (3H, d), 1.1 (7H, d).

10

Similarly prepared were

1-[2-[4-(6-Chloro-1H-indol-3-yl)-1-piperidinyl]ethyl]-3,4-dihydro-3-(1-methylethyl)-6-methylsulfonyl-1H-2,1,3-benzothiadiazone-2,2-dioxide.

15

¹H NMR (300 MHz, CDCl₃) δ 7.9 (1H, s), 7.8 (1H, dd), 7.6 (1H, d), 7.5 (1H, d), 7.3 (1H, d), 7.1 (2H, d), 7.0 (1H, dd), 6.9 (1H, d), 4.7 (2H, s), 4.2 (1H, m), 4.0 (2H, t), 3.1 (2H, d), 3.0 (3H, s), 2.7 (3H, m), 2.3 (2H, t), 2.1 (2H, d), 1.8 (2H, q), 1.1 (6H, d).

20

1-[2-[4-(6-Chloro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]ethyl]-3,4-dihydro-3-(1-methylethyl)-6-methylsulfonyl-1H-2,1,3-benzothiadiazine-2,2-dioxide.

5 ¹H NMR (300 MHz, CDCl₃) δ 8.1 (1H, s), 7.8 (1H, m), 7.7 (1H, d), 7.6 (1H, d), 7.1 (3H, m) 6.1 (1H, m), 4.7 (3H, m), 4.2 (1H, m), 4.1 (2H, t), 3.4 (2H, s), 3.0 (4H, s), 2.8 (4H, m), 2.6 (2H, s), 1.1 (6H, d).

10 1-[2-[4-(7-Fluoro-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]ethyl]-3,4-dihydro-3-(1-methylethyl)-6-methylsulfonyl-1H-2,1,3-benzothiadiazine-2,2-dioxide.

15 ¹H NMR (300 MHz, CDCl₃) δ 8.2 (1H, s), 7.8 (1H, dd), 7.6 (1H, m), 7.2 (2H, m), 7.1 (1H, m), 6.9 (1H, m), 6.2 (1H, m), 4.7 (2H, s), 4.2 (1H, m), 4.1 (2H, t), 3.4 (2H, s), 3.0 (3H, s), 2.8 (4H, m), 2.6 (2H, s), 1.1 (6H, d).

20 1-[2-[4-(7-Fluoro-1H-indol-3-yl)-1-piperidinyl]ethyl]-3,4-dihydro-3-(1-methylethyl)-6-methylsulfonyl-1H-2,1,3-benzothiadiazine-2,2-dioxide.

¹H NMR (300 MHz, CDCl₃) δ 8.2 (1H, s), 7.8 (1H, dd), 7.7 (1H, d), 7.4 (1H, d), 7.0 (2H, m), 6.9 (1H, m), 4.7 (2H, s), 4.2 (3H, m), 3.2 (2H, s), 3.0 (3H, s), 2.8 (2H, s), 2.6 (1H, s), 2.4 (2H, s), 1.3 (4H, s), 1.1 (6H, d).

1-[2-[4-(6,7-Difluoro-1H-indol-3-yl)-1-piperidinyl]ethyl]-3,4-dihydro-3-(1-methylethyl)-6-methylsulfonyl-1H-2,1,3-benzothiadiazine-2,2-dioxide.

¹H NMR (300 MHz, CDCl₃) δ 8.1 (1H, s), 7.8 (1H, dd), 7.7 (1H, d), 7.1 (1H, d), 6.9 (2H, m), 4.7 (2H, s), 4.2 (1H, m), 4.0 (2H, t), 3.1 (2H, d), 3.1 (3H, s), 2.7 (2H, t), 2.3 (2H, t), 2.0 (3H, m), 1.8 (2H, q), 1.1 (6H, d).

1-[2-[4-(6-Fluoro-7-methyl-1H-indol-3-yl)-3,6-dihydro-1(2H)-pyridinyl]ethyl]-3,4-dihydro-3-(1-methylethyl)-6-methylsulfonyl-1H-2,1,3-benzothiadiazine-2,2-dioxide.

¹H NMR (300 MHz, CDCl₃) δ 7.9 (1H, s), 7.8 (1H, dd), 7.6 (2H, m), 7.1 (2H, m), 6.9 (1H, t), 6.1 (1H, s), 4.7 (2H, s), 4.2 (1H, m), 4.1 (2H, t), 3.3 (2H,

s), 3.0 (3H, s), 2.8 (2H, t), 2.6 (2H, s), 2.4 (3H, s), 1.1 (6H, d).

5 The following Examples illustrate typical formulations containing the compound of the invention.

EXAMPLE 31

10 Tablets each containing 10 mg of active ingredient are made up as follows:

	Active ingredient	10 mg
	Starch	160 mg
15	Microcrystalline cellulose	100 mg
	Polyvinylpyrrolidone (as 10% solution in water)	13 mg
	Sodium carboxymethyl starch	14 mg
	Magnesium stearate	3 mg
20		_____
	Total	300 mg

The active ingredient, starch and cellulose are mixed thoroughly. The solution of
5 polyvinylpyrrolidone is mixed with the resultant powders and passed through a sieve. The granules so produced are dried and re-passed through a sieve. The sodium carboxymethyl starch and magnesium stearate are then added to the granules
10 which, after mixing, are compressed on a tablet machine to yield tablets each weighing 300 mg.

EXAMPLE 32


15 Capsules each containing 20 mg of medicament are made as follows:

	Active ingredient	20 mg
	Dried starch	178 mg
20	Magnesium stearate	2 mg
		—
	Total	200 mg

The active ingredient, starch and magnesium
stearate are passed through a sieve and filled into
5 hard gelatine capsules in 200 mg quantities.

CLAIMS



1. A compound of the formula:



5

in which R^1 and R^2 are each hydrogen, halo, cyano or methyl,

10 the dotted line represents an optional double bond,



15



where R^4 and R^5 are each hydrogen, C_{1-6} alkyl, cyclopropyl or cyclopropyl- C_{1-6} alkyl,

n is 0 or 1, and

R³ is -SR⁶, -SOR⁶, -SO₂R⁶, -COR⁶, -CH₂OH or
5 -CONHR⁷, where R⁶ is C₁₋₆ alkyl and R⁷ is hydrogen
or C₁₋₆ alkyl;

provided that when one of R¹ and R² is hydrogen and
the other is fluoro,

10

X is , Y is 

R⁴ and R⁵ are each hydrogen or C₁₋₆ alkyl,


15 and n is 0,

then R³ is not -COR⁶ or -CONHR⁷;

or a salt thereof.

20

2. A compound according to Claim 1, of the formula:




in which R^1 and R^2 are each hydrogen or fluoro,

5 R^3 is at the 6- or 7- position and is $-SOR^6$, $-SO_2R^6$
or $-COR^6$, where R^4 and R^6 are each C_{1-6} alkyl.

3. A compound according to Claim 2 in which R^1 is
fluoro, R^2 is hydrogen, R^3 is at the 6-position, R^4
10 is C_{1-6} alkyl, R^6 is methyl, and the dotted bond
represents a double bond.

4. A compound of the formula:



where R³ is -SOCH₃ or -SO₂CH₃, or a
pharmaceutically acceptable salt thereof.

5

5. A pharmaceutical formulation comprising a compound according to any of Claims 1 to 4, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent or carrier therefor.

10

6. A compound according to any of Claims 1 to 4, or a pharmaceutically acceptable salt thereof, for use as a pharmaceutical.

15


7. Use of a compound according to any of Claims 1 to 4, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a disorder of the central nervous system.

20

8. A method of treating a disorder of the central nervous system which comprises administering an effective amount of a compound according to Claim 1, or a pharmaceutically acceptable salt thereof.

5

9. A compound of the formula:




10

where n is 1, X and Y have the values given in Claim 1, and in which Z is (i) $-\text{CH}_2\text{W}$, where W is a leaving group, or (ii) Z is $-\text{CHO}$; or a salt thereof.

15

10. A compound of the formula








in which R^1 and R^2 are as defined in Claim 1, or a salt thereof.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁷ : C07D 417/14, 401/14, A61K 31/549, 31/5415, 31/475, 31/454, C07D 285/16, 285/10, 215/22, 215/36, 209/34</p>	<p>A3</p>	<p>(11) International Publication Number: WO 00/31074 (43) International Publication Date: 2 June 2000 (02.06.00)</p>
<p>(21) International Application Number: PCT/GB99/03836 (22) International Filing Date: 18 November 1999 (18.11.99) (30) Priority Data: 9825413.9 19 November 1998 (19.11.98) GB (71) Applicant: ELI LILLY AND COMPANY LIMITED [GB/GB]; Kingsclere Road, Basingstoke, Hampshire RG21 6XA (GB). (72) Inventors: FAIRHURST, John; 17 Hinton Fields, Kings Wor- thy, Winchester, Hampshire SO23 7QB (GB). GAL- LAGHER, Peter, Thaddeus; 27 Ryves Avenue, Yateley, Hampshire GU46 6FB (GB). MILES, Martin, Victor; 21 Wensleydale Gardens, Hampton, Middlesex TW12 2LU (GB). (74) Agent: HUDSON, Christopher, Mark; Eli Lilly and Company Limited, Lilly Research Centre, Erl Wood Manor, Windle- sham, Surrey GU20 6PH (GB).</p>		<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> (88) Date of publication of the international search report: 14 September 2000 (14.09.00)</p>

(54) Title: INDOLE DERIVATIVES AND THEIR USE AS SEROTONIN RECEPTOR LIGANDS



(57) Abstract

A pharmaceutical compound of formula (I) in which R¹ and R² are each hydrogen, halo, cyano or methyl, the dotted line represents an optional double bond, X is (1) or (2), Y is (3) or (4) where R⁴ and R⁵ are each hydrogen, C₁₋₆ alkyl, cyclopropyl or cyclopropyl-C₁₋₆ alkyl, n is 0 or 1, and R³ is -SR⁶, -SOR⁶, -SO₂R⁶, -COR⁶, -CH₂OH or -CONHR⁷, where R⁶ is C₁₋₆ alkyl and R⁷ is hydrogen or C₁₋₆ alkyl; provided that when one of R¹ and R² is hydrogen and the other is fluoro, X is (1), Y is (4), R⁴ and R⁵ are each hydrogen or C₁₋₆ alkyl, and n is 0, then R³ is not -COR⁶ or -CONHR⁷; and salts thereof.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 99/03836

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D417/14 C07D401/14 A61K31/549 A61K31/5415 A61K31/475
A61K31/454 C07D285/16 C07D285/10 C07D215/22 C07D215/36
C07D209/34

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 98 31686 A (LILLY CO ELI) 23 July 1998 (1998-07-23) cited in the application ---	1,5-8
A	DE 195 00 689 A (MERCK PATENT GMBH) 18 July 1996 (1996-07-18) claim 1 ---	1,5-8
X	GUILLAUME J ET AL: "(TETRAHYDRO-1,2,3,6 PYRIDINYL-4)-3 1H-INDOLES: SYNTHÈSE, PROPRIÉTÉS SÉROTONINÉRIQUES ET ANTI-DOPAMINÉRIQUES" EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY. CHIMICA THERAPEUTICA, FR, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, vol. 22, no. 1, page 33-43 XP000572286 ISSN: 0223-5234 compound 7 --- -/-	10

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

5 January 2000

Date of mailing of the international search report

12/01/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

De Jong, B

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 99/03836

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	EP 0 897 921 A (LILLY CO ELI) 24 February 1999 (1999-02-24) claim 1; examples ---	1-9
E	WO 99 58525 A (MILES MARTIN VICTOR ; SMITH COLIN WILLIAM (GB); FAIRHURST JOHN (GB)) 18 November 1999 (1999-11-18) claims; examples -----	1-9

INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB 99/03836

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 8
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim 8
is directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compounds.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 99/03836

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9831686	A	23-07-1998	AU 5569298 A	07-08-1998
			CA 2227132 A	17-07-1998
			CZ 9901510 A	15-09-1999
			EP 0854146 A	22-07-1998
			JP 10204090 A	04-08-1998
			NO 993372 A	08-07-1999
			ZA 9800300 A	10-09-1998
DE 19500689	A	18-07-1996	AU 704484 B	22-04-1999
			AU 4086296 A	18-07-1996
			CA 2166958 A	13-07-1996
			CN 1133840 A	23-10-1996
			CZ 9600093 A	17-07-1996
			EP 0722942 A	24-07-1996
			HU 9600071 A	28-09-1998
			JP 8253474 A	01-10-1996
			NO 960125 A	15-07-1996
			PL 312270 A	22-07-1996
			SK 4396 A	06-11-1996
			US 5670511 A	23-09-1997
			ZA 9600228 A	26-07-1996
EP 0897921	A	24-02-1999	US 5929072 A	27-07-1999
			AU 8743098 A	16-03-1999
			CA 2245331 A	22-02-1999
			WO 9910346 A	04-03-1999
			JP 11116572 A	27-04-1999
WO 9958525	A	18-11-1999	EP 0963983 A	15-12-1999